

Neifeld Docket No: TACT0001

Application No. : 09/666,068 Confirmation No. 6420
Patent No. : 6,379,666 Issued April 30, 2002
Applicant : Edward L. Tobinick
Filed : 12/11/2000
TC/A.U. : 1614
Examiner : Jarvis, William R. A.

37 CFR §1.78 Petition for Acceptance of an Unintentionally Delayed Claim for Priority
and Petition for Entry of an Amendment to the Specification in an Issued Application

This is a Petition to accept an unintentionally delayed claim of priority under 37 CFR 1.78(a)(3). The entire delay between the date the priority claim was due under paragraph 37 CFR 1.78 (a)(2)(ii) and the date of submission of this Petition was unintentional.

The fee required by 37 CFR 1.17(t) is submitted herewith.

An amendment to the specification correcting the reference to related applications is submitted herewith

A draft Certificate of Correction for U.S. 6,379,666 and the fee required by 37 CFR 1.20(a) are submitted herewith.

All of the elements required under 37 CFR 1.78(a)(3) have been presented, thus awarding a corrected priority chain in application Ser. No. 09/666,068 is proper.

I. STATEMENT OF THE RELIEF REQUESTED

The applicant petitions for acceptance of an unintentionally delayed claim for priority and for entry into this issued application of an amendment to correct the benefit claim under 35 U.S.C. §120.

The chain of priority in 09/666,068 is missing a reference to application 09/275,070. As explained below, the priority chain should refer to 09/275,070 between 09/476,643 and 09/256,388, and it should specify that 09/476,643 is a continuation-in-part of 09/275,070.

In an amendment submitted herewith, page 1 of the specification (the paragraph starting with "RELATED APPLICATIONS") is amended as follows (marked-up):

This application is a divisional of Ser. No. 09/476,643, filed Dec. 31, 1999, now U.S. Pat No. 6,177,077, which is a continuation-in-part of Serial No. 09/275,070, filed March 23, 1999, now U.S. Pat No. 6,015,557, which is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned.

II. MATERIAL FACTS

A. CHAIN OF APPLICATION FILINGS

1. On February 24, 1999, the applicant filed Serial No. 09/256,388, with an original U.S. inventor declaration.

2. On September 16, 1999, applicant filed a notice of express abandonment that stated:

"Re: S.N. 09/256,388 Applicant hereby abandons the above-identified application in favor of Appln. S.N. 09/275,070, which has been allowed by Examiner Jarvis."

3. Serial No. 09/275,070 was filed on March 23, 1999, and matured into U.S. 6,015,557 on January 18, 2000. The applicant filed an original U.S. inventor declaration in 09/275,070, which specifically referred to S.N. 09/256,388.

4. Applicant filed Serial No. 09/476,643 on December 31, 1999, which is prior to January 18, 2000, and was therefore co-pending with S.N. 09/275,070. Applicant filed an original U.S. inventor declaration attached to the specification in 09/476,643 that did not refer to any prior applications.

5. Page 1 of the '643 specification, under the heading "RELATED APPLICATION" stated erroneously that "This is a continuation-in-part of Application Serial No. 09/256,388, filed on February 24, 1999." This statement is erroneous because 09/256,388 had been expressly abandoned on September 16, 1999 (before the '643 application was filed) in favor of 09/275,070 which was still pending when the '643 application was filed.
6. On July 21, 2000, applicant filed a "new" (i.e. a second) original U.S. inventor declaration in 09/476,643 that specifically refers to 09/256,388 and to 09/275,070, thus correcting priority and preserving co-pendency throughout all applications in the chain.
7. Serial No. 09/476,643 matured into U.S. 6,177,077 on January 23, 2001. On page 1 of the patent specification, as amended on July 21, 2000, it states "This application is a continuation-in-part of Ser. No. 09/275,070, filed March 23, 1999, now U.S. Pat No. 6,015,557, which is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned."
7. Applicant first filed the subject divisional (Ser. No. 09/666,068) on September 19, 2000, but later was accorded an official filing date of December 11, 2000, which however is still prior to January 23, 2001. Thus divisional 09/666,068 was co-pending with its parent application 09/476,643. The applicant filed the same inventive specification, a copy of the U.S. inventor declaration from 09/476,643, and relied upon that copy of the original inventor declaration to secure the December 11, 2000 filing date.
8. On 12/06/2000, applicant filed a request for Correction of Filing Receipt stating erroneously: "THIS APPLICATION IS A DIV OF 09/476,643, DATED 12/31/1999, WHICH IS A CIP OF 09/256,388, DATED 2/24/1999, ABANDONED." This statement is erroneous because 09/476,643 is actually a continuation-in-part of Ser. No. 09/275,070, and cannot be a continuation-in-part of 09/256,388, due to lack of co-pendency, as explained above.
9. On 11/15/2001, the Related Application statement on page 1 of subject application 09/666,068 was amended by the Examiner (as indicated by handwritten, dated initials) to add the following underlined text: "This application is a divisional of Ser. No. 09/476,643, filed Dec. 31, 1999, now U.S. Pat No. 6,177,077, which is a continuation-in-part of Application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned." This statement is erroneous because

09/476,643 is actually a continuation-in-part of Ser. No. 09/275,070, and cannot be a continuation-in-part of 09/256,388, due to lack of co-pendency, as explained above.

11. On 02/22/2001, an Official Filing Receipt was issued in 09/666,068 stating "THIS APPLICATION IS A DIV OF 09/476,643, 12/31/1999, PAT 6,177,077 WHICH IS A CIP OF 09/256,388, 2/24/1999, ABANDONED." This statement is erroneous because 09/476,643 is in fact a continuation-in-part of Ser. No. 09/275,070, and cannot be a continuation-in-part. 09/256,388, due to lack of co-pendency, as explained above.

12. So in 09/666,068, the applicant's request for Correction of Filing Receipt (12/06/2000), the Examiner's amendment to the specification (11/15/2001), and the Official Filing Receipt (03/22/2001) are all incorrect. That is because 09/476,643 is actually a continuation-in-part of Serial No. 09/275,070, while 09/275,070 is a CIP of 09/256,388.

13. As a result of these facts the 09/666,068 application contains an erroneous priority chain.

B. USPTO RECORDS SHOWING THE BENEFIT CLAIM IN 09/666,068

14. Exhibit 1 is a copy of the 2 page transmittal letter, and page 1 of the specification filed on 09/19/2000 in application 09/666,068. The upper left hand corner of Exhibit 1 has a USPTO date stamp showing "09/19/00" The upper right hand corner shows the USPTO application number "09/666,068."

15. Exhibit 1, pages 1 and 2, indicate that 09/666,068 was filed as a Rule 60 divisional incorporating the prior specification and inventor declaration. Item 8 is checked, and amends the specification before the first line to recite "division of application number 09/476,643, filed Dec. 31, 1999."

16. Exhibit 1 page 3 shows the original first sentence of the specification, i.e., "This is a continuation-in-part of application Serial No. 09/256,388, filed on February 24, 1999" along with the Examiner's handwritten amendment dated 11/15/2001, revising the priority claim to recite "This application is a divisional of Ser. No. 09/476,643, filed Dec. 31, 1999, now U.S. Pat No. 6,177,077, which is a continuation-in-part of Application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned." (marked-up)

17. Exhibit 2, pages 1 and 2 shows the applicant filed a copy of the original U.S. inventor declaration from 09/476,643, signed by Edward L. Tobinick, M.D. on December 29, 1999, and relied upon that copy to secure the December 11, 2000 filing date.
18. Exhibit 2, page 3 shows applicant requested a correction of filing receipt, dated-stamped "12/06/2000," in stating erroneously: "THIS APPLICATION IS A DIV OF 09/476,643, DATED 12/31/1999, WHICH IS A CIP OF 09/256,388, DATED 2/24/1999, ABANDONED."
19. Exhibit 3, pages 3 - 4 show a two page transmittal letter, date-stamped "Dec 11, 2000" filed in response to the Notice to File Missing Parts, listing "A copy of the Declaration from the parent application (U.S. Serial No. 09/476,643)".
20. Exhibit 3, pages 1 is a Official Filing Receipt mailed "01/24/2001." Exhibit 3, page 2 is an Official Filing Receipt mailed "02/22/2001."
21. Application 09/666,068 issued as USP 6,379,666.
22. Exhibit 4 is a printout of the first two columns of USP 6,379,666.
23. Exhibit 4 shows that the first sentence of USP 6,379,666 recites "This application is a divisional of Ser. No. 09/476,643, filed Dec. 31, 1999, now U.S. Pat No. 6,177,077, which is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned."
24. **The foregoing facts show that the USPTO records show that application 09/666,068 is a divisional of 09/476,643.**

C. USPTO RECORDS SHOWING THE BENEFIT CLAIM IN 09/476,643

25. Exhibit 5, pages 1 and 2 shows the original inventor declaration from application 09/476,643, signed by Edward L. Tobinick, M.D., on December 29, 1999. Exhibit 5, page 3 is the first page of the PTO file history for application 09/476,643, stating in the examiner's handwriting verification that "THIS APPLN is a CIP OF 09/275,070 03/23/99 PAT 6,015,557 WHICH IS A CIP OF 09/256,388 02/24/99 ABN"
26. Exhibit 6, page 1 is a one page transmittal letter dated "December 31, 1999 BY EXPRESS MAIL" for a new application showing the filing of an original inventor's declaration. At the upper left is the date "12/31/99" and at the upper right is the serial number "09/476643". Exhibit 6, page 2 shows the first page of the specification, which one can see originally said

"This is a continuation-in-part of Application Serial No. 09/256,388, filed on February 24, 1990." This sentence was crossed-out by the examiner.

27. Exhibit 7, page 1 is the first page of the PTO File History, amended in handwriting by the examiner to state "This Appln is a CIP OF 09/275,070 PAT #6,015,557 WHICH IS A CIP OF 09/256,388 02/24/99 ABN." Exhibit 7, page 2 is another copy of the one page transmittal letter dated "December 31, 1999 BY EXPRESS MAIL." for a new application showing the filing of an original inventor's declaration. At the upper left is the date "12/31/99" and at the upper right is the serial number "09/476643". Exhibit 7, page 3 is an inventor declaration filed with the application. Exhibit 7, page 4 shows the first page of the specification as filed, which stated "This is a continuation-in-part of Application Serial No. 09/256,388, filed on February 24, 1990". This sentence was later crossed-out by the examiner.

28. Exhibit 8, page 1 is a Terminal Disclaimer over US 6,015,557, and page 2 is an original inventor declaration claiming benefit of application "09/275,070 March 23, 1999 U.S. Patent No. 6,015,557" and "09/256,388 February 24, 1999 Abandoned"

29. Exhibit 9, page 2 shows the handwritten amendment by the examiner, dated 8/24/2000 changing the first sentence of the specification to recite "This application is a continuation-in-part of Application Serial No. 09/275,070, filed on March 23, 1999, now U.S. Patent 6,015,557, which is a continuation-in-part of Application Ser. No. 09/256,388, filed on February 24, 1999, now abandoned"

30. Exhibit 10 is a printout of the first two columns of US 6,177,077, stating in the first paragraph that "This application is a continuation-in-part of Application Serial No. 09/275,070, filed on Mar 23, 1999, now U.S. Pat. No. 6,015,557, which is a continuation-in-part of Application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned."

31. The foregoing facts show that the USPTO records show that application 09/476,643 was a continuation-in-part of 09/275,070.

D. USPTO RECORDS SHOWING THE BENEFIT CLAIM IN 09/275,070

32. Exhibit 11, page 1 is a transmittal letter dated "March 23, 1999 BY EXPRESS MAIL." Page 2 is the first page of the specification as filed. Pages 3 and 4 are a copy of the original inventor declaration, claiming benefit under 35 USC 120 to "09/256,388 24 February 1999

pending” signed on 3-20-99 by two inventors, Dr. Edward L. Tobinick, and Arthur Jerome Tobinick. Pages 5 -8 are a copy of a Petition to Make Special filed March 23, 1999. At the upper right on page 5 is the serial number “09/257070” and the date “03/23/99”.

33. Exhibit 12 is a printout of the first two columns of US 6,015,557, stating in the first paragraph that “This application is a continuation-in-part of Application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned.”

34. **The foregoing facts show that the USPTO records show that application 09/275,070 was a continuation-in-part of 09/256,388.**

E. USPTO RECORDS SHOWING THE FILING DATE OF 09/256,388

35. Exhibit 13, page 3 is a copy of the first page USPTO file history for application 09/256,388, showing “FILING DATE 02/24/99.” Pages 1 - 2 show the original inventor declaration, dated February 21, 1999, signed by two inventors, Dr. Edward L. Tobinick, and Arthur Jerome Tobinick. In 09/256,388, inventor “Edward L. Tobinick, M.D.” is the same person as “Dr. Edward L. Tobinick” in 09/275,070 (and “Edward L. Tobinick, M.D.” in 09/476,643).

36. Exhibit 14 is another copy of the inventor declaration. Page 2 is transmittal letter dated “FEBRUARY 24, 1999 BY EXPRESS MAIL” listing the filing of an inventor declaration, and specification. Page 3 of Exhibit 14 is the first page of the specification as filed.

37. Exhibit 15, pages 1 - 2 is a Notice of Abandonment “mailed 09/27/99.” Exhibit 15, page 3 is communication by applicant dated 9/16/99 stating: “Re: S.N. 09/256,388 Applicant hereby abandons the above-identified application in favor of Appln. S.N. 09/275,070, which has been allowed by Examiner Jarvis.”

38. **The foregoing show that the USPTO records show that application 09/256,388 was filed on February 24, 1999 and abandoned on Sept. 16, 1999.**

F. FACTS WHY THE REQUESTED RELIEF IS NOT MOOT

39. Pending Tobinick application 12/714,205 claims priority to 09/666,068 as “a continuation of application Serial No. 11/262,528, filed on Oct. 28, 2005, which is a division of application Ser. No. 10/269,745, filed Oct. 9, 2002, now U.S. Pat. No. 6,982,089, which is a

continuation-in-part of application Ser. No. 09/841,844, filed on Apr. 25, 2001, now U.S. Pat. No. 6,537,549, which is a continuation-in-part of application Ser. No. 09/826,976, filed on Apr. 5, 2001, now U.S. Pat. No. 6,419,944, **which is a continuation-in-part of application Ser. No. 09/666,068, filed Dec. 11, 2000, now U.S. Pat. No. 6,379,666, which is a division of application Ser. No. 09/476,643, filed on Dec. 31, 1999, now U.S. Pat. No. 6,177,077, which is a continuation-in-part of application Ser. No. 09/275,070, filed on Mar. 23, 1999, now U.S. Pat. No. 6,015,557, which is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned.**" (emphasis added)

G. FACTS SHOWING THE FAILURE TO PROPERLY CLAIM BENEFIT WAS UNINTENTIONAL

40 The foregoing facts 1 - 39 show that failure to claim in this application priority to 09/666,068 was an unintentional clerical error.

H. FACTS RELATING TO THE LEGAL STANDARD FOR ENTRY OF CORRECTION OF BENEFIT CLAIMS

41 Exhibit 16 is a copy of pages from Section 1481.03 of the current version of the MPEP.

I. RELATED USPTO PROCEEDINGS

42. The applicant is presenting herewith an Amendment to correct benefit in prior application 09/666,068.

43. The applicant is filing herewith a corresponding request for a certificate of correction in the patent that issued from this application, U.S. Pat. 6,379,666.

III. REASONS WHY THE PETITION SHOULD BE GRANTED

On the merits, the petition should be granted because (1) the relief requested is not moot; (2) an amendment as to benefit in an issued application is submitted herewith, (3) all of the elements required under 37 CFR 1.78(a)(3) have been presented, so awarding a corrected priority chain in application Ser. No. 09/666,068 is proper, and (4) a request for the appropriate Certificate of Correction has been filed.

A.. STANDARD FOR GRANT OF PETITION

1. FORMAL MATTERS

This petition requests entry of an amendment in an issued application filed after November 29, 2000. Therefore petition under Rule 1.78 is proper.

(CX13 "Eighteen-Month Publication Questions and Answers"
<http://www.uspto.gov/patents/law/aipa/18month/18monthfaq.jsp#cx>)

The applicant is paying the 37 CFR 1.17(t) fee therefore via credit card upon EFS web submission of this petition.

2. THE PETITION IS NOT MOOT

The petition is not moot because, even though 09/666,068 is issued, a pending application claims priority to this application. Fact 39.

3. CRITERIA FOR CORRECTION OF BENEFIT

The amendment that this petition requests be entered corrects benefit. The requirements to obtain benefit and to correct benefit are governed by Rule 1.78. MPEP 1481.03 contains criteria for granting a certificate of correction correcting benefit in an issued patent. See the section titled "Correction of 35 U.S.C. 119 and 35 U.S.C. 120 Benefits." In view of the foregoing, this petition shows compliance with the criteria for correction of benefit under Rule 1.78.

B. THE APPLICANT HAS COMPLIED WITH THE CRITERIA FOR CLAIMING BENEFIT TO 09/666,068

1. THE APPLICANT HAS COMPLIED WITH THE REQUIREMENTS OF 37 C.F.R. 1.78

The following paragraphs in this subsection identify requirements in Rule 1.78 for claiming priority, and show compliance with those requirements.

37 CFR 1.78(a)(1) authorizes a claim to priority to prior filed applications only if the applications name at least one common inventor and disclose the claimed invention. The prior filed application is 09/666,068. The common inventor is Edward L. Tobinick, M.D. Facts 14-39.

37 CFR 1.78(a)(1)(i) and (ii) require the prior filed applications to be either international applications or applications entitled to a filing date. The prior filed applications is 09/666,068, which was entitled to and accorded a filing date. Exhibit 1, Facts 14 - 15.

37 CFR 1.78(a)(2)(i) requires a claim to priority to be present or amended to be present during the pendency of the application, unless the application was filed prior to November 29, 2000, and to state the relationship between the applications. This application is an application filed under 111(a) after November 29, 2000. Accordingly, the amendment submitted herewith provides the specific references and relationships to 09/476,643, which is a continuation-in-part of 09/275,070, which is a continuation-in-part of 09/256,388.

37 CFR 1.78(a)(2)(iii) requires the claim to priority be presented in an application data sheet or amendment to the first sentence of the specification following the title. The amendment submitted herewith provides the claim to priority to 09/666,068 in the first sentence of the specification following the title.

37 CFR 1.78(a)(3) authorizes an amendment claiming priority after the time periods specified by 1.78(a)(2)(ii) only if the late filing of the claim the priority was unintentionally delayed. The entire delay between the date the priority claim was due under paragraph 37 CFR 1.78 (a)(2)(ii) and the date of submission of this Petition was unintentional. Fact 40.

37 CFR 1.78 contains no other requirements applicable to grant of this petition. In view of the foregoing, this petition should be granted.

DATE: 3-30-2010

SIGNATURE: /RobertHahl#33,893/

PRINTED NAME: Robert W. Hahl, Ph.D.

Date/time code: March 30, 2010 (5:56pm)

Y:\Clients\TACT\TACT0001\Tobinick's parents\PetitionToCorrectPriority_6379666.wpd

PES, CROSS-NOTING, AND STATUS OF APPLICATION

201.06(a)

** PTO/SB/13 (11-00)

Approved for use through 5/30/99. OMB 0651-0033
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.60

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION	PRIOR APPLICATION EXAMINER	ART UNIT
TOBINICK 3.0-009(CIP)(DIVII)	CLASS SUBCLASS	Examiner William R.A. Jarvis	1614

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

This is a request for filing a ☐ continuation ☒ divisional application under 37 CFR 1.60, of pending prior Application Number 09/476,643, filed on 12/31/99, entitled THE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

1. Enclosed is a copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number 09/476,643 and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.181(a))	17	-20 =	--	x \$ =	\$ --
INDEPENDENT CLAIMS (37 CFR 1.182)	1	-3 =	--	x \$ =	\$ --
MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.183)				x \$ =	\$ --
				BASIC FEE (37 CFR 1.184)	+ \$345.00
				Total of above Calculations =	
				Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.29).	
				TOTAL =	\$345.00

2. ☒ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27
☐ is enclosed.
☒ was filed in prior application number 09/476,643 and such status is still proper and desired (37 CFR 1.28(a)).
3. ☐ The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.
4. ☒ A check in the amount of \$ 345 is enclosed.
5. ☒ Cancel in this application original claims 1-49 & 66-99 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
6. ☒ The inventor(s) of the invention being claimed in this application is (are):
Dr. Edward L. Tobinick
7. ☐ This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.60(b), the Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application:
8. ☒ Amend the specification by inserting before the first line the sentence: "This application is a ☐ continuation ☒ division of application number 09/476,643, filed Dec 31, 1999, (status, abandoned, pending, etc.)."

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 5/30/99. OMB 0851-0033
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.60, PAGE 2)

9. ☐ New formal drawings are enclosed.
10. ☐ Priority of foreign application number _____, filed on _____ in _____
 is claimed under 35 U.S.C. 119(a) - (d).
☐ The certified copy has been filed in prior application number ____ / _____, filed _____.
11. ☒ A preliminary amendment is enclosed.
12. ☐ The prior application is assigned of record to _____
13. ☐ Also enclosed:

14. ☒ The power of attorney in the prior application is to: EZRA SUTTON, P.A.
Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095

- a. ☐ The power of attorney appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☐ Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

☐ Customer Number

OR

Type Customer Number here

Firm or

☒ Individual Name

EZRA SUTTON, P.A.

Address Plaza 9, 900 Route 9

Address

City

Woodbridge

State

New Jersey

ZIP 07095

Country

Telephone (732) 634-3520

Fax (732) 634-3511

9-5-00

Date

Signature
EZRA SUTTON

Typed or printed name

- ☐ Inventor(s)
- ☐ Assignee of complete interest. Certification under 37 CFR 3.73(b) is enclosed.
- ☒ Attorney or agent of record
- ☐ Filed under 37 CFR 1.34(a) _____ 25,770
 Registration number if acting under 37 CFR 1.34(a) _____

5 **TNF INHIBITORS FOR THE TREATMENT OF
NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS**

RELATED APPLICATION

application is a divisional of 09/476,643, filed December 31, 1999, now U.S. Patent 6,177,077, which

This is a continuation-in-part of Application Serial No. 09/256,388, filed on
February 24, 1999, ^{now abandoned}
1

257
4/15/01

10 **FIELD OF THE INVENTION**

15 The present invention relates to tumor necrosis factor (TNF) antagonists or TNF
blockers for the treatment of neurological disorders, trauma, injuries or compression;
demyelinating neurological disorders, including multiple sclerosis; neurodegenerative
diseases, including Alzheimer's disease; muscular disorders; and disorders of the optic nerve
and retina (hereinafter "Neurologic and Related TNF Disorders"). More particularly, the
TNF antagonists, TNF inhibitors or TNF blockers, are used for the treatment, prevention or
amelioration of these "Neurologic and Related TNF Disorders" by modulating the action of
TNF in the human body. The use of these TNF antagonists or TNF blockers results in the
amelioration of these disorders and diseases and represents a novel use for this class of drugs.

20 **BACKGROUND OF THE INVENTION**

Neurological disorders due to demyelinating disease (e.g. multiple sclerosis), immune
disease, inflammation, trauma, or compression, occur in different clinical forms depending
upon the anatomic site and the cause and natural history of the physiological problem. For
example, in Alzheimer's disease the brain undergoes a serious form of neurodegeneration

Exhibit 2_Pages41-45fromIFW_0868068_666.



Applicant or Patentee: Edward L. TOBINICK, M.D. Attorney's
Serial or Patent No.: _____ Docket No.:
Filed or Issued: _____
Title: TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR DISORDERS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.2(f) AND 1.27(b) - INDEPENDENT INVENTOR**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the invention entitled TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

described in:

- ☒ the specification filed herewith
☐ Application Serial No. _____, filed _____
☐ Patent No. _____, issued _____

I have not assigned, granted, conveyed, or licensed and am under no obligation, under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern, or organization
☐ persons, concerns, or organizations listed below

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Edward L. TOBINICK, M.D.

NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
<u>Edward L. Tobinick</u>	<u>Edward L. Tobinick</u>	<u>Edward L. Tobinick</u>
Signature of Inventor	Signature of Inventor	Signature of Inventor

December 29, 1999

Date	Date	Date
_____	_____	_____

DECLARATION FOR PATENT APPLICATION

Docket No. TOBINICK
7.0-009 (CIP)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is ~~indicated~~) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, the specification of which RETINAL AND MUSCULAR DISORDERS

(check one) ☒ is attached hereto.☐ was filed on _____

Application Serial No. _____

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770Address all telephone calls to _____ at telephone no. (732) 634-3520

Address all correspondence to _____

EZRA SUTTON, P.A.Plaza 9, 900 Route 9Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Edward L. TOBINICK, M.D.Inventor's signature [Signature] Date December 29, 1999Residence Los Angeles, California 90024-6903 Citizenship United States of AmericaPost Office Address 100 UCLA Medical Plaza, Suite 205
Los Angeles, California 90024-6903

Full name of second joint inventor, if any _____

Second Inventor's signature _____

Date _____

Residence _____

Citizenship _____

Post Office Address _____



#5
7P
2/25/01

RECEIPT

RECEIVED

TOBINICK 3.0-009 (CIP) (DIV I)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BY FAX - 1-703-308-7751

In re patent application of:
EDWARD L. TOBINICK, M.D.

Serial No. 09/666,068

Group Art Unit 1614

Filed: September 19, 2000

Examiner

For: TNF INHIBITORS FOR THE
TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR DISORDERS

December 6, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

CORRECTION OF FILING RECEIPT

Sir:

Please issue a corrected filing receipt, and correct the
following data:

THIS APPLICATION IS A DIV OF 09/476,643, DATED 12/31/1999,
WHICH IS A CIP OF 09/256,388, DATED 2/24/1999, ABANDONED.

See the enclosed filing receipt.

Respectfully submitted,

EZRA SUTTON, P.A.

Ezra Sutton

EZRA SUTTON
Reg. No. 25,770

Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095
(732) 634-3520
ES/jmt

RECEIVED
JAN 12 '01
OIP E/JCVS



UNITED STATES PATENT AND TRADEMARK OFFICE

FILING DATE | GRP PART UNIT | FIL PER REC'D | ATTY DOCKET NO | DRAWINGS | TOT CLAIMS | IND CLAIMS |
09/19/2000 | 1614 | 345 | TOBINICK | 3:0-009 | 21 | 2

Ezra Sutton PA
Plaza 9 900 Route 9
Woodbridge, NJ 07095



Date Mailed: 11/15/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) Edward L. Tobinick, Los Angeles, CA :

Continuing Data as Claimed by Applicant
THIS APPLICATION IS A CIP OF 09/256,388 02/24/1999 ABN

Foreign Applications

If Required, Foreign Filing License Granted 11/15/2000

**** SMALL ENTITY ****

Title TNF inhibitors for the treatment of neurological, retinal and muscular disorders

Preliminary Class
514

Data entry by : HINES, BRENDA

Team : OIPE

Date: 11/15/2000



FILE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

 RECEIVED
 09/13/2001
 TECH CENTER 1600/2300

SERIAL NUMBER 09/666,068	FILING DATE 12/11/2000 RULE _	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. TOBINICK3.0-009 (CIP)(DIVI)
------------------------------------	--	---------------------	-------------------------------	--

APPLICANTS

Edward L. Tobinick, Los Angeles, CA ;

** CONTINUING DATA *****

 THIS APPLICATION IS A DIV OF 09/476,643 12/31/1999 PAT 6,177,077
 WHICH IS A CIP OF 09/256,388 02/24/1999 ABN

** FOREIGN APPLICATIONS *****

 IF REQUIRED, FOREIGN FILING LICENSE
 GRANTED ** 11/02/2000

** SMALL ENTITY **

Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	STATE OR COUNTRY CA	SHEETS DRAWING _	TOTAL CLAIMS 16	INDEPENDENT CLAIMS 1
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged Examiner's Signature _____ Initials _____				

ADDRESS

 EZRA SUTTON, P.A.
 Plaza 9, 900 Route 9
 Woodbridge ,NJ 07095

TITLE

TNF inhibitors for the treatment of neurological, retinal and muscular disorders

FILING FEE RECEIVED 410	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit

Exhibit 3_Pages 34-39fromIFW_09666068_665.pdf




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP/ART UNIT	FILE FEE REC'D	ATTY.DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/656,068	12/11/2000	1614	410	TOBINICK3.0- 009(CIP)(DIV)I		16	1

CORRECTED FILING RECEIPT



0000000005701748

EZRA SUTTON, P.A.
Plaza 9, 900 Route 9
Woodbridge, NJ 07095

Date Mailed: 01/24/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Edward L. Tobinick, Los Angeles, CA ;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A DIV OF 09/476,643 12/31/1999 PAT 6,177,077
WHICH IS A CIP OF 09/256,388 02/24/1999 ABN

Foreign Applications

If Required, Foreign Filing License Granted 11/02/2000

** SMALL ENTITY **

Title

TNF inhibitors for the treatment of neurological, retinal and muscular disorders

Preliminary Class

514

Data entry by : BURSE, JANICE

Team : OIPE

Date: 01/24/2001





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20531
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/666,068	12/11/2000	1614	410	TOBINICK3.0-008(CIP)(DIVI		16	1

CONFIRMATION NO. 6420

FILING RECEIPT



0000000006791231

EZRA SUTTON, P.A.
Plaza 9, 900 Route 9
Woodbridge, NJ 07095

Date Mailed: 02/22/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Edward L. Tobinick, Los Angeles, CA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A DIV OF 09/476,843 12/31/1999 PAT 6,177,077
WHICH IS A CIP OF 09/256,388 02/24/1999 ABN

Foreign Applications

If Required, Foreign Filing License Granted 11/02/2000

Projected Publication Date: 05/31/2001


Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

TNF inhibitors for the treatment of neurological, retinal and muscular disorders



2/28/01

Section
#3



TOBINICK 3.0-009 (CIP) (DIV II)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
EDWARD L. TOBINICK, M.D.

Serial No. 09/666,068 : Group Art Unit 1614

Filed: September 19, 2000 : Examiner

For: TNF INHIBITORS FOR THE : December 6, 2000
TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR DISORDERS

Assistant Commissioner for Patents
Washington, D.C. 20231

Attention: Customer Service Center
Initial Patent Examination Division

RESPONSE

Sir:

This is in response to the "Notice to File Missing Parts of
Nonprovisional Application," dated November 2, 2000.


Enclosed for filing are the following:

1. Page 54, which was missing from the application;
2. A copy of the Declaration from the parent application (U.S.
Serial No. 09/476,643);
3. A copy of the Verified Statement for a Small Entity from
the parent application (U.S. Serial No. 09/476,643);
4. The surcharge fee of \$65 for a small entity; and
5. A copy of the Notice to File Missing Parts of
Nonprovisional Application.

It is requested that this application be given a new filing date upon receipt of this Response.

Respectfully submitted,

EZRA SUTTON, P.A.



EZRA SUTTON, Reg. No. 25,770

Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095

(732) 634-3520

ES/jmt

Enclosures

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231 ON

Date December 6, 2000
By Judith M. Grains

US 6,379,666 B1

1

TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

RELATED APPLICATION

This application is a divisional of Ser. No. 09/476,643, filed Dec. 31, 1999, now U.S. Pat. No. 6,177,077, which is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned.

FIELD OF THE INVENTION

The present invention relates to tumor necrosis factor (TNF) antagonists or TNF blockers for the treatment of neurological disorders, trauma, injuries or compression; demyelinating neurological disorders, including multiple sclerosis; neurodegenerative diseases, including Alzheimer's disease; muscular disorders; and disorders of the optic nerve and retina (hereinafter "Neurologic and Related TNF Disorders"). More particularly, the TNF antagonists, TNF inhibitors or TNF blockers, are used for the treatment, prevention or amelioration of these "Neurologic and Related TNF Disorders" by modulating the action of TNF in the human body. The use of these TNF antagonists or TNF blockers results in the amelioration of these disorders and diseases and represents a novel use for this class of drugs.

BACKGROUND OF THE INVENTION

Neurological disorders due to demyelinating disease (e.g., multiple sclerosis), immune disease, inflammation, trauma, or compression, occur in different clinical forms depending upon the anatomic site and the cause and natural history of the physiological problem. For example, in Alzheimer's disease the brain undergoes a serious form of neurodegeneration of unknown etiology. Common to all of these disorders is the fact that they can cause permanent neurological damage, that damage can occur rapidly and be irreversible, and that current treatment of these conditions is unsatisfactory, often requiring surgery and/or the use of pharmacologic agents, which are often not completely successful.

These neurological conditions include acute spinal cord trauma, spinal cord compression, spinal cord hematomas, cord contusion (these cases are usually traumatic, such as motorcycle accidents or sports injuries); nerve compression, the most common condition being a herniated disc causing sciatic nerve compression, neuropathy, and pain; but also including cervical disc herniation, causing nerve compression in the neck; acute or chronic spinal cord compression from cancer (this is usually due to metastases to the spine, such as from prostate, breast or lung cancer); autoimmune disease of the nervous system; and demyelinating diseases, the most common condition being multiple sclerosis.

Steroid drugs such as corticosteroids are used to treat many of the aforementioned neurological problems and conditions are particularly hazardous because they are used either at high dosage, with a corresponding increasing risk of side effects, or because they are used chronically, also increasing their adverse effects. Lastly, steroids are only partially effective or completely ineffective.

Tumor necrosis factor (TNF), a naturally occurring cytokine, plays a central role in the inflammatory response and in immune injury. TNF is formed by the cleavage of a precursor transmembrane protein, forming soluble molecules which aggregate to form trimolecular complexes. These complexes then bind to receptors found on a variety

2

of cells. Binding produces an array of pro-inflammatory effects, including release of other pro-inflammatory cytokines, including interleukin (IL)-6, IL-8, and IL-1; release of matrix metalloproteinases; and up regulation of the expression of endothelial adhesion molecules, further amplifying the inflammatory and immune cascade by attracting leukocytes into extravascular tissues. TNF is now well established as key in the pathogenesis of rheumatoid arthritis (RA) and Crohn's Disease.

Specific inhibitors of TNF, only recently commercially available, now provide the possibility of therapeutic intervention in TNF mediated diseases. Dramatic therapeutic success has already been demonstrated with infliximab, a chimeric anti-TNF monoclonal antibody (mAb), in treating Crohn's Disease and RA; and with etanercept, a recombinant fusion protein consisting of two soluble TNF receptors joined by the Fc fragment of a human IgG1 molecule, in treating RA and Psoriatic Arthritis. Other specific anti-TNF agents are under development, including D2E7 (a human anti-TNF mAb), CDP 571 (a chimeric, but 95% humanized, anti-TNF mAb), and a pegylated soluble TNF type I receptor. Additionally, thalidomide has been demonstrated to be a potent anti-TNF agent. Further, anti-TNF therapies may include gene therapy and the development of selective inhibitors of the TNF-alpha converting enzyme.

As with other organ systems, TNF has been shown to have a key role in the central nervous system. There is a need for TNF inhibitors that will open a new realm of therapeutic possibilities for a wide variety of neurological and related disorders. These disorders are diverse and include inflammatory and autoimmune disorders of the nervous system, including multiple sclerosis, Guillain Barre syndrome, and myasthenia gravis; degenerative disorders of the nervous system, including Alzheimer's disease, Parkinson's disease and Huntington's disease; disorders of related systems of the retina and of muscle, including optic neuritis, macular degeneration, diabetic retinopathy, dermatomyositis, amyotrophic lateral sclerosis, and muscular dystrophy; and injuries to the nervous system, including traumatic brain injury, acute spinal cord injury, and stroke.

The limited ability of the body to effect repair after injury to the nervous system, the devastating nature of these diseases and the lack of effective therapy all highlight the importance of early therapy aimed at preventing or limiting neuronal destruction. Anti-TNF therapies are ideally suited to this task because they have been demonstrated to dramatically limit inflammation by interrupting the inflammatory cascade at a fundamental level.

There remains a need for a new pharmacologic treatment of these aforementioned physiological problems of the nervous system associated with autoimmune disease, demyelinating diseases, neurodegenerative diseases, trauma, injuries and compression with the pharmacological use of TNF antagonists or TNF blockers, which are greatly beneficial for the large number of patients whom these conditions affect. Drugs which are powerful TNF blockers are etanercept, infliximab, pegylated soluble TNF Receptor Type I (PEGA-TNF-R1), other agents containing soluble TNF receptors, CDP571 (a humanized monoclonal anti-TNF-alpha antibody), thalidomide analogues and other phosphodiesterase IV inhibitors. Etanercept or infliximab may be used for the immediate, short term and long term (acute and chronic) blockade of TNF in order to minimize neurological damage mediated by TNF dependent processes occurring in the aforementioned neurological disorders. The use of these TNF antagonists or TNF blockers would result in the amelioration of these physiological neurological problems.

DECLARATION FOR PATENT APPLICATION

Docket No. TOBINICK
3.0-009 (CIP)

As a below named inventor, I hereby declare that:

Exhibit 5, Pages 170-173 from IFW_69476543_077.pdf

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, the specification of which RETINAL AND MUSCULAR DISORDERS (check one) ☒ is attached hereto.

☐ was filed on _____ as
Application Serial No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770

Address all telephone calls to _____ at telephone no. (732) 634-3520

Address all correspondence to _____

EZRA SUTTON, P.A.

Plaza 9, 900 Route 9

Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Edward L. TOBINICK, M.D.
Inventor's signature [Signature] Date December 29, 1999
Residence Los Angeles, California 90024-6903 Citizenship United States of America
Post Office Address 100 UCLA Medical Plaza, Suite 205
Los Angeles, California 90024-6903

Full name of second joint inventor, if any _____
Second Inventor's signature _____ Date _____
Residence _____ Citizenship _____
Post Office Address _____

Applicant or Patentee: Edward L. TOBINICK, M.D.

Attorney's

Serial or Patent No.:

Docket No.:

Filed or Issued:

Title: TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR DISORDERS**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.2(f) AND 1.27(b) - INDEPENDENT INVENTOR)**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the invention entitled TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

described in:

☒ the specification filed herewith☐ Application Serial No. _____, filed _____☐ Patent No. _____, issued _____

I have not assigned, granted, conveyed, or licensed and am under no obligation, under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

☒ no such person, concern, or organization☐ persons, concerns, or organizations listed below

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Edward L. TOBINICK, M.D.

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of Inventor

Signature of Inventor

Signature of Inventor

December 29, 1999

Date

Date

Date

SERIAL NUMBER 09/476,643	FILING DATE 12/31/99	CLASS 535 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. TOBINICK.3.0
APPLICANT EDWARD L. TOBINICK, LOS ANGELES, CA.				
CONTINUING DOMESTIC DATA*** VERIFIED THIS APPLN IS A CIP OF 09/275,070 03/23/99 PAT 6,015,557 WHICH IS A CS OF 09/256,388 02/24/99 ABN **371 (NAT'L STAGE) DATA***** VERIFIED NONE				
FOREIGN APPLICATIONS*** VERIFIED NONE				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED 02/07/00 ** SMALL ENTITY **				
Foreign Priority claimed 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no Verified and Acknowledged <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY CA	SHEETS DRAWING 0	TOTAL CLAIMS 99	INDEPENDENT CLAIMS 8
ADDRESS EZRA SUTTON PA PLAZA 9 900 ROUTE 9 WOODBRIDGE NJ 07095				
TITLE TNT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL RETINAL AND MUSCULAR DISORDERS				
FILING FEE RECEIVED \$501	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	

01-05-00

Exhibit 6_Pages112-114fromIFW_09476643_077.pdf

LAW OFFICES

EZRA SUTTON, P. A.

A PROFESSIONAL CORPORATION

PLAZA 9

900 ROUTE 9

WOODBRIIDGE, NEW JERSEY 07095

PATENTS
TRADEMARKS
COPYRIGHTSEZRA SUTTON*
OF COUNSEL
ROBERT A. GREEN
DAVID L. DAVIS

December 31, 1999

*MEMBER OF N.J. AND N.Y. BARS

BY EXPRESS MAIL

(732) 634-3520
CABLE: TRADEPAT
FAX: (732) 634-3511Assistant Commissioner for Patents
Washington, D.C. 20231File No.: TOBINICK 3.0-009 (CIP)
Inventor(s): Edward L. TOBINICK
Title: TNFIIINHIBITORS FOR THE TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR DISORDERS

Assignee: None

Dear Sir:

Enclosed herewith are the following documents in the above-
identified application for a Letters Patent of the United States:

2	Pages of Abstract	* Verified Statement for Small Entity Status
9	Pages of Specification	Declaration, Power of Attorney & Petition
9	Number of Claims	Two (2) return-addressed postcards
-	Sheets of Drawings	(PLEASE PROVIDE FILING DATE & SERIAL NUMBER)
-	Assignment for Recording (attached to copy of this letter)	
X	PETITION TO MAKE SPECIAL; LIST OF PRIOR ART CITED BY APPLICANT; 5 PRIOR	
	5 PRIOR ART PATENTS; FEE OF \$130	


Check No. 3884 in the amount of \$510, calculated as follows:
(\$380 + \$130)

Basic Fee (**Large Business \$760.00) (*Small Business \$380.00)	\$ <u>380</u>
Additional Fees:	
Total number of claims <u>99</u>	
Total number of claims in excess of 20, <u>79</u> times (**\$18)(*\$9)	<u>711</u>
Number of independent claims <u>8</u>	
Number of independent claims minus 3, <u>5</u> times (**\$78)(*\$39)	<u>195</u>
Assignment recording fee (\$40)	
Multiple dependent claims (**\$260) (*\$130)	<u>\$1,286</u>
PETITION TO MAKE SPECIAL	<u>130</u>
TOTAL filing and assignment recording fees	<u>\$1,416</u>

CONVENTION DATE _____ for _____ Appln. No. _____
is claimed.

Priority Document: _____ Enclosed _____ Will follow

Respectfully submitted,



EZRA SUTTON, Reg No. 25,770

ES/jmt
Enclosures


12/31/99

09476643-125199

 12/31/99
 09/476643
 S. N. C. 059
 PTO
 12/31/99

5
**TNF INHIBITORS FOR THE TREATMENT OF
NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS**

RELATED APPLICATION

 This is a continuation-in-part of Application Serial No. 09/256,388, filed on February 24, 1999.

10
FIELD OF THE INVENTION

15
The present invention relates to tumor necrosis factor (TNF) antagonists or TNF blockers for the treatment of neurological disorders, trauma, injuries or compression; demyelinating neurological disorders, including multiple sclerosis; neurodegenerative diseases, including Alzheimer's disease; muscular disorders; and disorders of the optic nerve and retina (hereinafter "Neurologic and Related TNF Disorders"). More particularly, the TNF antagonists, TNF inhibitors or TNF blockers, are used for the treatment, prevention or amelioration of these "Neurologic and Related TNF Disorders" by modulating the action of TNF in the human body. The use of these TNF antagonists or TNF blockers results in the amelioration of these disorders and diseases and represents a novel use for this class of drugs.

20
BACKGROUND OF THE INVENTION

Neurological disorders due to demyelinating disease (e.g. multiple sclerosis), immune disease, inflammation, trauma, or compression, occur in different clinical forms depending upon the anatomic site and the cause and natural history of the physiological problem. For example, in Alzheimer's disease the brain undergoes a serious form of neurodegeneration

2



Bib Data Sheet

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231**FILE COPY**

SERIAL NUMBER 09/476,643	FILING DATE 12/31/1999 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. TOBINICK.3.0
APPLICANTS EDWARD L. TOBINICK, LOS ANGELES, CA ; ** CONTINUING DATA ***** This Appln is a CIPED WHICH - THIS APPLICATION IS A CIP OF 09/256,388 02/24/1999 ABN ** FOREIGN APPLICATIONS ***** IF REQUIRED, FOREIGN FILING LICENCE GRANTED ** SMALL ENTITY ** ** 02/07/2000 Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after mmt Allowance Verified and Acknowledged <u>AW</u> Examiner's Signature Initials ADDRESS EZRA SUTTON PA PLAZA 9 900 ROUTE 9 WOODBRIDGE, NJ 07095 TITLE TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS				
FILING FEE RECEIVED 510	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input checked="" type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other <input type="checkbox"/> Credit	

 RECEIVED
 MAR 27 2000
 TECH CENTER 1600/2900

 PAT #
 9/275,070,605,557

8/24/00

01-05-00

66/13/21
 3994/09
 PTO S. U. 503
 Jc503

12/31/99

Jc503 U. S. PTO
 12/31/99

LAW OFFICES
EZRA SUTTON, P. A.

A PROFESSIONAL CORPORATION

PLAZA 9

900 ROUTE 9

WOODBRIIDGE, NEW JERSEY 07095

PATENTS
 TRADEMARKS
 COPYRIGHTS

(732) 634-3520
 CABLE: TRADEPAT
 FAX: (732) 634-3511

EZRA SUTTON*
 OF COUNSEL
 ROBERT A. GREEN
 DAVID L. DAVIS

December 31, 1999

*MEMBER OF N.J. AND N.Y. BARS

BY EXPRESS MAIL

Assistant Commissioner for Patents
 Washington, D.C. 20231

File No.: TOBINICK 3.0-009 (CIP)
 Inventor(s): Edward L. TOBINICK
 Title: TNF-INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL,
 RETINAL AND MUSCULAR DISORDERS

Assignee: None

Dear Sir:

Enclosed herewith are the following documents in the above-
 identified application for a Letters Patent of the United States:

2	Pages of Abstract	* Verified Statement for Small Entity Status
9	Pages of Specification	Declaration, Power of Attorney & Petition
99	Number of Claims	Two (2) return-addressed postcards
-	Sheets of Drawings	(PLEASE PROVIDE FILING DATE & SERIAL NUMBER)
-	Assignment for Recording (attached to copy of this letter)	
X	PETITION TO MAKE SPECIAL; LIST OF PRIOR ART CITED BY APPLICANT;	
	5 PRIOR ART PATENTS; FEE OF \$130	

Check No. 3887 in the amount of \$\$510, calculated as follows:
 (\$380 + \$130)

Basic Fee (**Large Business \$760.00) (*Small Business \$380.00) \$ 380


Additional Fees:

Total number of claims	99	
Total number of claims in excess of 20,	79	times (**\$18)(\$*9) <u>711</u>
Number of independent claims	8	
Number of independent claims minus 3,	5	times (**\$78)(\$*39) <u>195</u>
Assignment recording fee (\$40)		
Multiple dependent claims (**\$260) (*\$130)		<u>\$1,286</u>
PETITION TO MAKE SPECIAL		<u>130</u>
TOTAL filing and assignment recording fees		<u>\$1,416</u>

CONVENTION DATE _____ for _____ Appln. No. _____
 is claimed.

Priority Document: _____ Enclosed _____ Will follow

Respectfully submitted,



EZRA SUTTON, Reg No. 25,770

ES/jmt
 Enclosures

Applicant or Patentee: Edward L. TOBINICK, M.D.

Attorney's

Serial or Patent No.:

Docket No.:

Filed or Issued:

Title: TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL,RETINAL AND MUSCULAR DISORDERS**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.2(f) AND 1.27(b) - INDEPENDENT INVENTOR**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the invention entitled TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

described in:

- ☒ the specification filed herewith
☐ Application Serial No. _____, filed _____
☐ Patent No. _____, issued _____

I have not assigned, granted, conveyed, or licensed and am under no obligation, under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern, or organization
☐ persons, concerns, or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Edward L. TOBINICK, M.D.

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of Inventor

Signature of Inventor

Signature of Inventor

December 29, 1999

Date

Date

Date

5 **TNF INHIBITORS FOR THE TREATMENT OF**
 NEUROLOGICAL, RETINAL AND MUSCULAR DISORDERS

RELATED APPLICATION

 This is a continuation-in-part of Application Serial No. 09/256,388, filed on
February 24, 1999.

10 FIELD OF THE INVENTION

 The present invention relates to tumor necrosis factor (TNF) antagonists or TNF
blockers for the treatment of neurological disorders, trauma, injuries or compression;
demyelinating neurological disorders, including multiple sclerosis; neurodegenerative
diseases, including Alzheimer's disease; muscular disorders; and disorders of the optic nerve
15 and retina (hereinafter "Neurologic and Related TNF Disorders"). More particularly, the
TNF antagonists, TNF inhibitors or TNF blockers, are used for the treatment, prevention or
amelioration of these "Neurologic and Related TNF Disorders" by modulating the action of
TNF in the human body. The use of these TNF antagonists or TNF blockers results in the
amelioration of these disorders and diseases and represents a novel use for this class of drugs.

20 BACKGROUND OF THE INVENTION

 Neurological disorders due to demyelinating disease (e.g. multiple sclerosis), immune
disease, inflammation, trauma, or compression, occur in different clinical forms depending
upon the anatomic site and the cause and natural history of the physiological problem. For
example, in Alzheimer's disease the brain undergoes a serious form of neurodegeneration


Exhibit 8_Pages23-24fromIPW_09475643_077.pdf

OFFICE

1490

MANUAL OF PATENT EXAMINING PROCEDURE

Approved for use through 10/31/99, Class 6021-000
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT		PTO/5528 (10-99) Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Docket Number (Optional) TOBINICK 3 0-009 (618)
In re Application of:	EDWARD L. TOBINICK	
Application No.	09/476,643	
Filed:	December 31, 1999	
For:	TNF INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL RETINAL AND MUSCULAR DISORDERS	
<p>The owner, EDWARD L. TOBINICK, a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,015,557. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.</p> <p>In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer. In the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.</p> <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney of record.</p> <div style="text-align: right; margin-top: 10px;">  Signature July 20, 2000 Date EZRA SUTTON Typed or printed name </div> <p><input checked="" type="checkbox"/> Terminal disclaimer fee under 37 CFR 1.20(d) included.</p> <p><small>*Certification under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/5528 may be used for making this certification. See MPEP § 324.</small></p>		

Caution: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any statements on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Reactions Communications for Patents, Washington, DC 20231.

July 1998

1400-62

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

OFFICIAL

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter, which is claimed and for which a patent is sought on the invention entitled **MUSCULAR DISORDERS FOR THE TREATMENT OF NEUROLOGICAL, RETINAL AND**, the specification of which

(check one) ☒ is attached hereto.

☐ was filed on _____ as
 Application Serial No. _____
 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed
(Number)	(Country)	(Day/Month/Year Filed)	Yes No
(Number)	(Country)	(Day/Month/Year Filed)	Yes No
(Number)	(Country)	(Day/Month/Year Filed)	Yes No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/256,388	February 24, 1999	Abandoned
(Application Serial No.) 09/256,388	(Filing Date) March 23, 1999	(Status—patented, pending, abandoned) U.S. Patent No. 6,015,557
(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770

Address all telephone calls to _____ at telephone no. (732) 634-3520
 Address all correspondence to _____
EZRA SUTTON, P.A.
Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Edward G. Tobinick, M.D.
 Inventor's signature [Signature] Date July 19, 2000
 Residence Los Angeles, California Citizenship United States of America
 Post Office Address 100 UCLA Medical Plaza, Suite 205
Los Angeles, California 90024-6903

Full name of second joint inventor, if any _____
 Second Inventor's signature _____ Date _____
 Residence _____ Citizenship _____
 Post Office Address _____

(Supply similar information and signature for third and subsequent joint inventors.)

LAW OFFICES

EZRA SUTTON, P. A. FAX RECEIVED

A PROFESSIONAL CORPORATION

PLAZA 9

900 ROUTE 9

WOODBIDGE, NEW JERSEY 07095

JUL 24 2000

GROUP 1600

PATENTS
TRADEMARKS
COPYRIGHTS(732) 634-3520
FAX: (732) 634-3511EZRA SUTTON-
JOSEPH SUTTON
OF COUNSEL
ROBERT A. GREEN
DAVID L. DAVIS

*MEMBER OF N.J. AND N.Y. BARS

Date

7/20/00

OFFICIAL

TO:

EXR JARVIS

FAX NO.

703-308-4556

FROM:

EZRA SUTTON

FAX NO.

1-732-634-3511

PHONE:

1-732-634-3520

TOTAL NUMBER
OF PAGES:

8

Amendment Enclosed.

Jr. Sutton

TOBINICK 3.0-009 (CIP)

OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BY FAX AND MAIL

In re patent application of:
EDWARD L. TOBINICK

Serial No.: 09/476,643

Group Art Unit 1614

Filed: December 31, 1999

Examiner William R. A. Jarvis

For: TNF INHIBITORS FOR THE
TREATMENT OF NEUROLOGICAL,
RETINAL AND MUSCULAR
DISORDERS

July 20, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231AMENDMENT

Sir:

This is in response to the first Office Action.

IN THE SPECIFICATION:

Please amend the first sentence of the specification as follows:

application
 -- This is a continuation-in-part of Application Serial No. *09/275,070*
March 23, 1999 U.S. Patent *6,015,557*, which is a continuation-in-part of
February 24, 1999 now abandoned, and Application Serial No. *09/275,070* now U.S. Patent
now abandoned *09/256,388*, filed *February 24, 1999*,
No. 6,015,557.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
 BEING DEPOSITED WITH THE UNITED STATES POSTAL
 SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
 ASSISTANT COMMISSIONER FOR PATENTS
 WASHINGTON, D.C. 20231 GM

DATE

BY

US 6,177,077 B1

TNT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

RELATED APPLICATION

This application is a continuation-in-part of application Ser. No. 09/275,070, filed on Mar. 23, 1999, now U.S. Pat. No. 6,015,557, which is a continuation-in-part of application Ser. No. 09/256,388, filed Feb. 24, 1999 now abandoned.

FIELD OF THE INVENTION

The present invention relates to tumor necrosis factor (TNF) antagonists or TNF blockers for the treatment of neurological disorders, trauma, injuries or compression; demyelinating neurological disorders, including multiple sclerosis; neurodegenerative diseases, including Alzheimer's disease; muscular disorders; and disorders of the optic nerve and retina (hereinafter "Neurologic and Related TNF Disorders"). More particularly, the TNF antagonists, TNF inhibitors or TNF blockers, are used for the treatment, prevention or amelioration of these "Neurologic and Related TNF Disorders" by modulating the action of TNF in the human body. The use of these TNF antagonists or TNF blockers results in the amelioration of these disorders and diseases and represents a novel use for this class of drugs.

BACKGROUND OF THE INVENTION

Neurological disorders due to demyelinating disease (e.g. multiple sclerosis), immune disease, inflammation, trauma, or compression, occur in different clinical forms depending upon the anatomic site and the cause and natural history of the physiological problem. For example, in Alzheimer's disease the brain undergoes a serious form of neurodegeneration of unknown etiology. Common to all of these disorders is the fact that they can cause permanent neurological damage, that damage can occur rapidly and be irreversible, and that current treatment of these conditions is unsatisfactory, often requiring surgery and/or the use of pharmacologic agents, which are often not completely successful.

These neurological conditions include acute spinal cord trauma, spinal cord compression, spinal cord hematoma, cord contusion (these cases are usually traumatic, such as motorcycle accidents or sports injuries); nerve compression, the most common condition being a herniated disc causing sciatic nerve compression, neuropathy, and pain; but also including cervical disc herniation, causing nerve compression in the neck; acute or chronic spinal cord compression from cancer (this is usually due to metastases to the spine, such as from prostate, breast or lung cancer); autoimmune disease of the nervous system; and demyelinating diseases, the most common condition being multiple sclerosis.

Steroid drugs such as cortisone that are used to treat many of the aforementioned neurological problems and conditions are particularly hazardous because they are used either at high dosage, with a corresponding increasing risk of side effects, or because they are used chronically, also increasing their adverse effects. Lastly, steroids are only partially effective or completely ineffective.

Tumor necrosis factor (TNF), a naturally occurring cytokine, plays a central role in the inflammatory response and in immune injury. TNF is formed by the cleavage of a precursor transmembrane protein, forming soluble molecules which aggregate to form trimolecular complexes. These complexes then bind to receptors found on a variety of cells. Binding produces an array of pro-inflammatory

effects, including release of other pro-inflammatory cytokines, including interleukin (IL)-6, IL-8, and IL-1; release of matrix metalloproteinases; and up regulation of the expression of endothelial adhesion molecules, further amplifying the inflammatory and immune cascade by attracting leukocytes into extravascular tissues. TNF is now well established as key in the pathogenesis of rheumatoid arthritis (RA) and Crohn's Disease.

Specific inhibitors of TNF, only recently commercially available, now provide the possibility of therapeutic intervention in TNF mediated diseases. Dramatic therapeutic success has already been demonstrated with infliximab, a chimeric anti-TNF monoclonal antibody (mAb), in treating Crohn's Disease and RA; and with etanercept, a recombinant fusion protein consisting of two soluble TNF receptors joined by the Fc fragment of a human IgG1 molecule, in treating RA and Psoriatic Arthritis. Other specific anti-TNF agents are under development, including D2E7 (a human anti-TNF mAb), CDP 571 (a chimeric, but 95% humanized, anti-TNF mAb), and a pegylated soluble TNF type 1 receptor. Additionally, thalidomide has been demonstrated to be a potent anti-TNF agent. Further, anti-TNF therapies may include gene therapy and the development of selective inhibitors of the TNF-alpha converting enzyme.

As with other organ systems, TNF has been shown to have a key role in the central nervous system. There is a need for TNF inhibitors that will open a new realm of therapeutic possibilities for a wide variety of neurological and related disorders. These disorders are diverse and include inflammatory and autoimmune disorders of the nervous system, including multiple sclerosis, Guillain Barre syndrome, and myasthenia gravis; degenerative disorders of the nervous system, including Alzheimer's disease, Parkinson's disease and Huntington's disease; disorders of related systems of the retina and of muscle, including optic neuritis, macular degeneration, diabetic retinopathy, dermatomyositis, amyotrophic lateral sclerosis, and muscular dystrophy; and injuries to the nervous system, including traumatic brain injury, acute spinal cord injury, and stroke.

The limited ability of the body to effect repair after injury to the nervous system, the devastating nature of these diseases and the lack of effective therapy all highlight the importance of early therapy aimed at preventing or limiting neuronal destruction. Anti-TNF therapies are ideally suited to this task because they have been demonstrated to dramatically limit inflammation by interrupting the inflammatory cascade at a fundamental level.

There remains a need for a new pharmacologic treatment of these aforementioned physiological problems of the nervous system associated with autoimmune disease, demyelinating diseases, neurodegenerative diseases, trauma, injuries and compression with the pharmacological use of TNF antagonists or TNF blockers, which are greatly beneficial for the large number of patients whom these conditions affect.

Drugs which are powerful TNF blockers are etanercept, infliximab, pegylated soluble TNF Receptor Type 1 (PEGs TNF-R1), other agents containing soluble TNF receptors, CDP571 (a humanized monoclonal anti-TNF-alpha antibodies), thalidomide, phosphodiesterase 4 (IV) inhibitor thalidomide analogues and other phosphodiesterase IV inhibitors. Etanercept or infliximab may be used for the immediate, short term and long term (acute and chronic) blockade of TNF in order to minimize neurological damage mediated by TNF dependent processes occurring in the aforementioned neurological disorders. The use of these TNF antagonists or TNF blockers would result in the amelioration of these physiological neurological problems.

1c655 U.S. PRO
03/23/99

A

LAW OFFICES
EZRA SUTTON, P. A.

A PROFESSIONAL CORPORATION

PLAZA 9
900 ROUTE 9

WOODBRIIDGE, NEW JERSEY 07095

EZRA SUTTON*
OF COUNSEL
ROBERT A. GREEN
DAVID L. DAVIS

March 23, 1999

BY EXPRESS MAIL

PATENTS
TRADEMARKS
COPYRIGHTS

(732) 634-3520
CABLE: TRADEPAT
FAX: (732) 634-3511

*MEMBER OF N.J. AND N.Y. BARS

Assistant Commissioner for Patents
Washington, D.C. 20231

File No.: TOBINICK 3.0-007 (CIP)
Inventor(s): Dr. Edward L. Tobinick
Title: TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE
TREATMENT OF NEUROLOGICAL DISORDERS

Assignee: None

Dear Sir:

Enclosed herewith are the following documents in the above-identified application for a Letters Patent of the United States:

<u>1</u> Pages of Abstract	<u>X</u> Verified Statement for Small Entity Status
<u>21</u> Pages of Specification	Declaration, Power of Attorney & Petition
<u>47</u> Number of Claims	Two (2) return-addressed postcards
<u>none</u> Sheets of Drawings	(PLEASE PROVIDE FILING DATE & SERIAL NUMBER)
<u>none</u> Assignment for Recording (attached to copy of this letter)	
<u>X</u> PETITION TO MAKE SPECIAL; LIST OF PRIOR ART CITED BY APPLICANT; 3 PRIOR ART PATENTS; FEE (\$130)	

Check No. 3002 in the amount of \$753.00, calculated as follows:

Basic Fee (**Large Business \$760.00) (*Small Business \$380.00)	<u>\$380.00</u>
Additional Fees:	
Total number of claims <u>47</u>	
Total number of claims in excess of 20, <u>27</u> times (**\$18)(*\$9)	<u>243.00</u>
Number of independent claims <u>2</u>	
Number of independent claims minus 3, <u>--</u> times (**\$78)(*\$39)	<u>--</u>
Assignment recording fee (\$40)	<u>--</u>
Multiple dependent claims (**\$260) (*\$130)	<u>--</u>
TOTAL filing and assignment recording fees	<u>\$623.00</u>
PETITION TO MAKE SPECIAL FEE	<u>130.00</u>
CONVENTION DATE _____ for _____ Appln. No. _____	<u>\$753.00</u>

is claimed.

Priority Document: _____ Enclosed _____ Will follow

Respectfully submitted,

Ezra Sutton

EZRA SUTTON, Reg No. 25,770

ES/jmt
Enclosures

PRO
S N 6455
03/23/99

TUMOR NECROSIS FACTOR ANTAGONISTS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

RELATED APPLICATION

5 This is a continuation-in-part of Application Serial No.
09/956,388, filed on February 24, 1999.

FIELD OF THE INVENTION

10 The present invention relates to tumor necrosis factor (TNF)
antagonists or TNF blockers for the treatment of neurological
disorders, trauma, injuries or compression; or demyelinating
15 neurological disorders, including multiple sclerosis. More
particularly, the TNF antagonists or TNF blockers, with or without
the concurrent administration of methotrexate or Leflunomide, are
used in a new treatment of these disorders by inhibiting the action
of TNF in the cells of the human body. The use of these TNF
antagonists or TNF blockers with methotrexate or Leflunomide
results in the amelioration of these neurological conditions.

BACKGROUND OF THE INVENTION

20 Neurological disorders due to demyelinating disease (e.g.
multiple sclerosis), immune disease, inflammation, trauma, or
compression, occur in different clinical forms depending upon the
anatomic site and the cause and natural history of the
physiological problem. Common to all of these disorders is the
fact that they can cause permanent neurological damage, that damage
25 can occur rapidly and be irreversible, and that current treatment
of these conditions is unsatisfactory, often requiring surgery

As a below named inventor, I hereby that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT, the specification of which OF NEUROLOGICAL DISORDERS

(check one) ☒ is attached hereto.☐ was filed on _____

Application Serial No. _____

and was amended on _____

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/256,388	24 February 1999	pending
(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770

Address all telephone calls to _____ at telephone no. (732) 634-3520

Address all correspondence to _____

EZRA SUTTON, P.A.

Plaza 9, 900 Route 9

Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Dr. Edward L. TOBINICK

Inventor's signature [Signature] Date 3-20-99

Residence Los Angeles, California 90024-6903 Citizenship United States of America

Post Office Address 100 UCLA Medical Plaza, Suite 205

Los Angeles, California 90024-6903

Full name of second joint inventor, if any Arthur Jerome TOBINICK

Second Inventor's signature [Signature] Date 3-20-99

Residence Los Angeles, California 90024-6903 Citizenship United States of America

Post Office Address 100 UCLA Medical Plaza, Suite 205

Los Angeles, California 90024-6903

Dr. Edward L. TOBINICK
Arthur J. TOBINICK

Applicant or Patentee:
Serial or Patent No.:
Filed or Issued:
Title:

Attorney's
Docket No.: TOBINICK
3.0-007 (cip)

TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE
TREATMENT OF NEUROLOGICAL DISORDERS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.2(f) AND 1.27(b)) - INDEPENDENT INVENTOR

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

described in:

[X] the specification filed herewith
[] Application Serial No. _____, filed _____
[] Patent No. _____, issued _____

I have not assigned, granted, conveyed, or licensed and am under no obligation, under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

[X] no such person, concern, or organization
[] persons, concerns, or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME
ADDRESS

[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

FULL NAME
ADDRESS

[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

FULL NAME
ADDRESS

[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Dr. Edward L. TOBINICK

Arthur Jerome TOBINICK

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of Inventor

Signature of Inventor

Signature of Inventor

3-20-99

3-20-99

Date

Date

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: :
DR. EDWARD L. TOBINICK, et al :
Serial No. : Group Art Unit
Filed: : Examiner
For: TUMOR NECROSIS FACTOR : March 23, 1999
ANTAGONISTS FOR THE :
TREATMENT OF NEUROLOGICAL :
DISORDERS :



Assistant Commissioner for Patents
Washington, D.C 20231

PETITION TO MAKE SPECIAL
(MPEP Section 708.02)

Sir:

Applicant hereby files this Petition to make special this application for purposes of examination and payment of the issue fee, on the grounds of a pre-examination search. Applicant also submits the petition fee.

The application presents claims directed to a single invention. In case the Examiner believes that there is more than one invention, applicant hereby elects without traverse Claims 27 to 47.

SEARCH AREAS

A pre-examination search was made of the records of the U.S. Patent Office by applicants attorney, Ezra Sutton. The field of search included Class 424, Subclasses 85.1, 133.1, 134.1, 143.1,

04/01/1999 PALLER
00000022 09275079
135.00
03 FC:122

144.1, 145.1, and 158.1; Class 435, Subclasses 69.1, 69.7, 172.3, and 240.27; and Class 530, Subclasses 350, 351, 387.1, 387.3, 388.2, 388.23, 388.4, 866, and 868. Also, a computer search was performed using the terms TNF and tumor necrosis factor.

INVENTION SEARCHED

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

PATENTS SELECTED IN SEARCH

U.S. Patent Nos.: 5,605,690
 5,656,272
 5,795,967

A copy of each patent is enclosed.

DISCUSSION OF PATENTS

U.S. Patent No. 5,605,690 discloses using TNF antagonists to suppress TNF-dependent inflammatory diseases, such as arthritis. However, this reference does not disclose treating the specific neurological disorders claimed in the present application.

U.S. Patent No. 5,656,272 discloses using TNF antagonists to treat Crohn's disease. However, this reference does not disclose treating the specific neurological disorders claimed in the present application.


U.S. Patent No. 5,795,967 discloses using TNF antagonists to treat certain autoimmune diseases, such as arthritis, systemic lupus, and Crohn's disease. However, this reference does not disclose treating the specific neurological disorders claimed in the present application.

CONCLUSION

None of the prior art patents disclose or teach the specific subject matter recited in independent Claims 1 or 27, or render them obvious. Accordingly, this Petition should be granted.

Respectfully submitted,

EZRA SUTTON, P.A.



EZRA SUTTON
Reg. No. 25,770

Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095
(732) 634-3520

ES/jmt

Enclosures

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO
09/275,070	03/23/1999	424	1614	TOBINICK-3.0

APPLICANT
 EDWARD L TOBINICK, LOS ANGELES, CALIFORNIA; ARTHUR JEROME TOBINICK,
 LOS ANGELES, CALIFORNIA.

CONTINUING DOMESTIC DATA***
 VERIFIED THIS APPLN IS A CIP OF 09/256,388 02/24/1999

371 (NAT'L STAGE) DATA***
 VERIFIED

FOREIGN APPLICATIONS***
 VERIFIED

FOREIGN FILING LICENSE GRANTED 05/07/1999

SMALL ENTITY

Foreign priority claimed 35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
Verified and acknowledged Examiner's Name _____ Initials _____		CA	0	47	2

ADDRESS
 EZRA SUTTON P A
 PLAZA 9
 900 ROUTE 9
 WOODBRIDGE , NJ 07095

TITLE
 TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

FILING FEE RECEIVED \$**623	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of Time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit _____
--------------------------------	---	---

6,015,557

1

TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

RELATED APPLICATION

This is a continuation-in-part of application Ser. No. 09/256,388, filed on Feb. 24, 1999, now abandoned.

FIELD OF THE INVENTION

The present invention relates to tumor necrosis factor (TNF) antagonists or TNF blockers for the treatment of neurological disorders, trauma, injuries or compression; or demyelinating neurological disorders, including multiple sclerosis. More particularly, the TNF antagonists or TNF blockers, with or without the concurrent administration of methotrexate or Leflunomide, are used in a new treatment of these disorders by inhibiting the action of TNF in the cells of the human body. The use of these TNF antagonists or TNF blockers with methotrexate or Leflunomide results in the amelioration of these neurological conditions.

BACKGROUND OF THE INVENTION

Neurological disorders due to demyelinating disease (e.g. multiple sclerosis), immune disease, inflammation, trauma, or compression, occur in different clinical forms depending upon the anatomic site and the cause and natural history of the physiological problem. Common to all of these disorders is the fact that they can cause permanent neurological damage, that damage can occur rapidly and be irreversible, and that current treatment of these conditions is unsatisfactory, often requiring surgery and/or the use of pharmacologic agents, which are often not completely successful.

These neurological conditions include acute spinal cord trauma, spinal cord compression, spinal cord hematoma, cord contusion (these cases are usually traumatic, such as motorcycle accidents or sports injuries); nerve compression, the most common condition being a herniated disc causing sciatic nerve compression, neuropathy, and pain, but also including cervical disc herniation, causing nerve compression in the neck; carpal tunnel syndrome (non-RA); acute or chronic spinal cord compression from cancer (this is usually due to metastases to the spine, such as from prostate, breast or lung cancer); autoimmune disease of the nervous system; and demyelinating diseases, the most common condition being multiple sclerosis.

Steroid drugs such as cortisone that are used to treat the aforementioned neurological problems and conditions are particularly hazardous because they are used either at high dosage, with a corresponding increasing risk of side effects, or because they are used chronically, also increasing their adverse effects. Lastly, steroids are only partially effective or completely ineffective.

There remains a need for a new pharmacologic treatment of these aforementioned physiological problems of the nervous system associated with autoimmune disease, demyelinating diseases, trauma, injuries and compression with the pharmacological use of TNF antagonists or TNF blockers, which are greatly beneficial for the large number of patients whom these conditions affect. Two new drugs which are powerful TNF blockers are etanercept and infliximab. Etanercept or infliximab may be used for the immediate, short term and long term (acute and chronic) blockade of TNF in order to minimize neurologic damage mediated by TNF dependent processes occurring in the aforementioned neu-

2

rological disorders. The use of these TNF antagonists or TNF blockers would result in the amelioration of these physiological neurological problems. Concurrent administration of methotrexate or Leflunomide with either etanercept or infliximab is the preferred treatment for demyelinating diseases and certain other neurological disorders.

DESCRIPTION OF THE PRIOR ART

Pharmacologic chemical substances, compounds and agents which are used for the treatment of neurological disorders, trauma, injuries and compression having various organic structures and metabolic functions have been disclosed in the prior art. For example, U.S. Pat. Nos. 5,756,482 and 5,774,022 to ROBERTS et al disclose methods of attenuating physical damage to the nervous system and to the spinal cord after injury using steroid hormones or steroid precursors such as pregnenolone, and pregnenolone sulfate in conjunction with a non-steroidal anti-inflammatory substance such as indomethacin. These prior art patents do not teach the use of a TNF antagonist or TNF blocker for the suppression and inhibition of the action of TNF in the human body to treat neurological disease, trauma, injury or compression, or autoimmune neurologic disease as in the present invention.

U.S. Pat. No. 5,605,690 to JACOBS discloses a method for treating TNF-dependent inflammatory diseases such as arthritis by administering a TNF antagonist, such as soluble human TNFR (a sequence of amino acids), to a human. This prior art patent does not teach the use of a TNF antagonist or TNF blocker for the suppression and inhibition of the action of TNF in the human body to treat neurological disease, trauma, injury or compression, or demyelinating neurologic disease, as in the present invention.

U.S. Pat. No. 5,656,272 to LE et al discloses methods of treating TNF-alpha-mediated Crohn's disease using chimeric anti-TNF antibodies. This prior art patent does not teach the use of a TNF antagonist or TNF blocker for the suppression and inhibition of the action of TNF in the human body to treat neurological trauma, injury or compression, or autoimmune neurologic disease, as in the present invention.

U.S. Pat. No. 5,650,396 discloses a method of treating multiple sclerosis (MS) by blocking and inhibiting the action of TNF in a patient. This prior art patent does not teach the use of the TNF antagonist as in the present invention.

None of the prior art patents disclose or teach the use of the TNF antagonist or TNF blocker of the present invention with the concurrent administration of methotrexate or Leflunomide for suppression and inhibition of the action of TNF in a human to treat neurological disease, trauma, injury or compression, or demyelinating neurologic disease, in which the TNF antagonist gives the patient a better opportunity to heal, slows disease progression, prevents neurological damage, or otherwise improves the patient's health.

Accordingly, it is an object of the present invention to provide a TNF antagonist, with or without the concurrent administration of methotrexate or Leflunomide, for a new pharmacologic treatment of neurological disorders, trauma, injuries and compression affecting the nervous system of the human body, or demyelinating neurologic disease, such that the use of these TNF antagonists will result in the amelioration of these neurological conditions.

Another object of the present invention is to provide a TNF antagonist, with or without the concurrent administration of methotrexate or Leflunomide, for providing suppression and inhibition of the action of TNF in a human to treat neurological injury, trauma or compression, or demyelinating neurologic disease.

DECLARATION FOR PATENT APPLICATION

Docket No. TOBINICK
3.0-007

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT, the specification of whichOF NEUROLOGICAL DISORDERS(check one) ☒ is attached hereto.☐ was filed on _____

Application Serial No. _____

and was amended on _____

as _____

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770Address all telephone calls to _____ at telephone no. (732) 634-3520

Address all correspondence to _____

EZRA SUTTON, P.A.Plaza 9, 900 Route 9Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	<u>Dr. Edward L. TOBINICK</u>
Inventor's signature	<u>[Signature]</u> Date <u>X FEBRUARY 21, 1999</u>
Residence	<u>Los Angeles, California 90024-6903</u> Citizenship <u>United States of America</u>
Post Office Address	<u>100 UCLA Medical Plaza, Suite 205</u> <u>Los Angeles, California 90024-6903</u>
Full name of second joint inventor, if any	<u>ARTHUR JEROME TOBINICK</u>
Second Inventor's signature	<u>[Signature]</u> Date <u>FEBRUARY 21, 1999</u>
Residence	<u>LOS ANGELES, CALIFORNIA 90024-6903</u> Citizenship <u>USA</u>
Post Office Address	<u>100 UCLA MEDICAL PLAZA, SUITE 205</u> <u>LOS ANGELES, CALIFORNIA 90024-6903</u>

(Supply similar information and signature for third and subsequent joint inventors.)

Applicant or Patentee: Dr. Edward L. TOBINICK / Arthur J. Tobinick Attorney's
Serial or Patent No.: _____ Docket No.:
Filed or Issued: _____ TOBINICK 3.0-007
Title: TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE
TREATMENT OF NEUROLOGICAL DISORDERS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.2(f) AND 1.27(b) - INDEPENDENT INVENTOR**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the invention entitled TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

described in:
☒ the specification filed herewith
☐ Application Serial No. _____, filed _____
☐ Patent No. _____, issued _____

I have not assigned, granted, conveyed, or licensed and am under no obligation, under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

☒ no such person, concern, or organization
☐ persons, concerns, or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION



FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Dr. Edward L. TOBINICK ARTHUR JEROME TOBINICK

NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
		
Signature of Inventor	Signature of Inventor	Signature of Inventor
<u>X</u> <u>Feb. 21, 1999</u>	<u>Feb. 21, 1999</u>	
Date	Date	Date

SERIAL NUMBER 09/256,388	FILING DATE 02/24/99	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. 3.0-007
-----------------------------	-------------------------	--------------	------------------------	--------------------------------

APPLICANT

EDWARD L. TOBINICK, LOS ANGELES, CA.

CONTINUING DOMESTIC DATA***
VERIFIED

371 (NAT'L STAGE) DATA***
VERIFIED

FOREIGN APPLICATIONS***
VERIFIED

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 03/15/99 ** SMALL ENTITY **

Foreign Priority claimed 35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY CA	SHEETS DRAWING 0	TOTAL CLAIMS 24	INDEPENDENT CLAIMS 1
Verified and Acknowledged Examiner's Initials _____ Initials _____						

ADDRESS

EZRA SUTTON
PLAZA 9 ROUTE 9
WOODBIDGE NJ 07095

TITLE

TUMOR NECROSIS FACTORS ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL
DISORDERS

FILING FEE RECEIVED \$416	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
-------------------------------------	---	---

DECLARATION FOR PATENT APPLICATION

Docket No. TOBINICK
3.0-007

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled TUMOR NECROSIS FACTOR ANTAGONISTS FOR THE TREATMENT, the specification of which OF NEUROLOGICAL DISORDERS

(check one) ☒ is attached hereto.☐ was filed on _____ asApplication Serial No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) _____ (Filing Date) _____ (Status—patented, pending, abandoned)

(Application Serial No.) _____ (Filing Date) _____ (Status—patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ezra Sutton, Reg. No. 25,770Address all telephone calls to _____ at telephone no. (732) 634-3520

Address all correspondence to _____


EZRA SUTTON, P.A.Plaza 9, 900 Route 9Woodbridge, New Jersey 07095

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Dr. Edward L. TOBINICK
 Inventor's signature [Signature] Date February 21, 1989
 Residence Los Angeles, California 90024-6903 Citizenship United States of America
 Post Office Address 100 UCLA Medical Plaza, Suite 205
Los Angeles, California 90024-6903

Full name of second joint inventor, if any ARTHUR JEROME TUSIMICK
 Second Inventor's signature [Signature] Date February 21, 1989
 Residence Los Angeles, California 90024-6903 Citizenship USA
 Post Office Address 100 UCLA Medical Plaza, Suite 205
Los Angeles, California 90024-6903

02/24/99



1-639 U.S. PAT. & TM. OFF. OF COUNSEL AT
ROBERT A. GREEN
AND L. DAVIS

*MEMBER OF N.J. AND N.Y. BARS

LAW OFFICES

EZRA SUTTON, P. A.

A PROFESSIONAL CORPORATION

PLAZA 9

900 ROUTE 9

WOODBRIIDGE, NEW JERSEY 07095

1-639 U.S. PAT. & TM. OFF. OF COUNSEL AT

09/256388



PATENTS
TRADEMARKS
COPYRIGHTS

(732) 634-3520
CABLE: TRADEPAT
FAX: (732) 634-3511

February 24, 1999

BY EXPRESS MAIL

Assistant Commissioner for Patents
Washington, D.C. 20231

File No.: TOBINICK 3.0-007
Inventor(s): Dr. Edward L. Tobinick
Title: TUMOR NECROSIS FACTORS ANTAGONISTS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

Assignee: None

Dear Sir:

Enclosed herewith are the following documents in the above-identified application for a Letters Patent of the United States:

1	Pages of Abstract	<input checked="" type="checkbox"/> Verified Statement for Small Entity Status
16	Pages of Specification	Declaration, Power of Attorney & Petition
24	Number of Claims	Two (2) return-addressed postcards
--	Sheets of Drawings	(PLEASE PROVIDE FILING DATE & SERIAL NUMBER)
--	Assignment for Recording	(attached to copy of this letter)

Check No. _____ in the amount of \$416.00, calculated as follows:

Basic Fee (**Large Business \$760.00) (*Small Business \$380.00)	\$380.00
Additional Fees:	
Total number of claims <u>24</u>	
Total number of claims in excess of 20, <u>4</u> times (**\$18)(*\$9)	<u>36.00</u>
Number of independent claims <u>1</u>	
Number of independent claims minus 3, <u>--</u> times (**\$78)(*\$39)	<u>--</u>
Assignment recording fee (\$40)	<u>--</u>
Multiple dependent claims (**\$260) (*\$130)	<u>--</u>
	\$416.00
TOTAL filing and assignment recording fees	<u> </u>

CONVENTION DATE _____ for _____ Appln. No. _____
is claimed.

Priority Document: Enclosed Will follow

Respectfully submitted,

EZRA SUTTON, Reg No. 25,770

ES/jmt
Enclosures

**TUMOR NECROSIS FACTOR ANTAGONISTS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS**

FIELD OF THE INVENTION

5 The present invention relates to tumor necrosis factor (TNF)
antagonists or TNF blockers for the treatment of neurological
disorders, trauma, injuries or compression; or autoimmune
neurological disorders. More particularly, the TNF antagonists or
TNF blockers are used in a new treatment of these disorders by
10 inhibiting the action of TNF in the cells of the human body. The
use of these TNF antagonists or TNF blockers results in the
amelioration of these neurological conditions.

BACKGROUND OF THE INVENTION

Neurological disorders due to demyelinating disease, immune
disease, inflammation, trauma, or compression, occur in different
clinical forms depending upon the anatomic site and the cause and
natural history of the physiological problem. Common to all of
these disorders is the fact that they can cause permanent
neurological damage, that damage can occur rapidly and be
20 irreversible, and that current treatment of these conditions is
unsatisfactory, often requiring surgery and/or the use of
pharmacologic agents, which are often not completely successful.

These neurological conditions include acute spinal cord
trauma, spinal cord compression, spinal cord hematoma, cord
25 contusion (these cases are usually traumatic, such as motorcycle
accidents or sports injuries); nerve compression, the most common
condition being a herniated disc causing sciatic nerve compression,

09256348-022499


**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/256,388	02/24/99	TOBINICK	E 3.0-007

HM12/0927

 EZRA SUTTON
PLAZA 9 ROUTE 9
WOODBIDGE NJ 07095

EXAMINER
JARVIS, W

ART UNIT	PAPER NUMBER
1614	

DATE MAILED: 09/27/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Notice of Abandonment

Application No.
09/256,388

Applicant

Tobinick


Examiner
William R. A. Jarvis

Group Art Unit
1614



This application is abandoned in view of:

- ☐ applicant's failure to timely file a proper response to the Office letter mailed on _____.
- ☐ A response (with a Certificate of Mailing or Transmission of _____) was received on _____, which is after the expiration of the period for response (including a total extension of time of _____ month(s)) which expired on _____.
- ☐ A proposed response was received on _____, but it does not constitute a proper response to the final rejection.
(A proper response to a final rejection consists only of: a timely filed amendment which places the application in condition for allowance; a Notice of Appeal; or the filing of a continuing application under 37 CFR 1.62 (FWC)).
- ☐ No response has been received.
- ☐ applicant's failure to timely pay the required issue fee within the statutory period of three months from the mailing date of the Notice of Allowance.
- ☐ The issue fee (with a Certificate of Mailing or Transmission of _____) was received on _____.
- ☐ The submitted issue fee of \$ _____ is insufficient. The issue fee required by 37 CFR 1.18 is \$ _____.
- ☐ The issue fee has not been received.
- ☐ applicant's failure to timely file new formal drawings as required in the Notice of Allowability.
- ☐ Proposed new formal drawings (with a Certificate of Mailing or Transmission of _____) were received on _____.
- ☐ The proposed new formal drawings filed _____ are not acceptable.
- ☐ No proposed new formal drawings have been received.
- ☐ the express abandonment under 37 CFR 1.62(g) in favor of the FWC application filed on _____.
- ☒ the letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
- ☐ the letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
- ☐ the decision by the Board of Patent Appeals and Interferences rendered on _____ and because the period for seeking court review of the decision has expired and there are no allowed claims.
- ☐ the reason(s) below:


WILLIAM R. A. JARVIS
PRIMARY EXAMINER
ART UNIT 1614

LAW OFFICES
EZRA SUTTON, P. A.
A PROFESSIONAL CORPORATION
PLAZA 9
900 ROUTE 9
WOODBRIDGE, NEW JERSEY 07095

EZRA SUTTON*
OF COUNSEL
ROBERT A. GREEN
DAVID L. DAVIS
JEFFREY I. KAPLAN

*MEMBER OF N.J. AND N.Y. BARS

OFFICIAL
and. Jones
9/16/99 #2

PATENTS
TRADEMARKS
COPYRIGHTS

(732) 634-3520
CABLE: TRADEPAT
FAX: (732) 634-3511

Date

9/16/99

TO:

EXR. WILLIAM JARVIS

FAX NO.

703-308-7924

FROM:

EZRA SUTTON

FAX NO.

1-732-634-3511

PHONE: 1-732-634-3520

TOTAL NUMBER
OF PAGES:

1

Re: S.N. 09/256, 388

Applicant hereby abandons the
above-identified application in
favor of Appl. S.N. 09/275, 070,
which has been allowed by
Examiner Jarvis.

Ezra Sutton
REG. NO. 25770

1481.03

MANUAL OF PATENT EXAMINING PROCEDURE

agreeing to the change of inventorship in the patent, such statement must comply with the requirements of 37 CFR 1.324(b) and (4) the fee set forth in 37 CFR 1.20(b). This petition lacks item(s) [7].

[8]

Supervisory Patent Examiner,

Art Unit [9],

Technology Center [10]

[11]

Examiner Note:

1. If each of the four specified items has been submitted but one or more is insufficient, the petition should be denied. See paragraph 10.17. However, if the above noted deficiency can be cured by the submission of a renewed petition, a dismissal would be appropriate.
2. If the petition includes a request for suspension of the rules (37 CFR 1.183) of one or more provisions of 37 CFR 1.324 that are required by the statute (35 U.S.C. 256), form paragraph 10.18 should follow this form paragraph.
3. In bracket 7, pluralize as necessary and insert the item number(s) which are missing.
4. In bracket 11, insert correspondence address of record.
5. This form paragraph is printed with the USPTO letterhead.

¶ 10.17 Petition Under 37 CFR 1.324, Denied

In re Patent No. [1] :

Issue Date [2] : **DECISION DENYING PETITION**Appl. No. [3] : *37 CFR 1.324*

Filed: [4] :

For: [5] :

This is a decision on the petition filed [6] to correct inventorship under 37 CFR 1.324.

The petition is denied

[7]

[8]

Supervisory Patent Examiner,

Art Unit [9],

Technology Center [10]

[11]

Examiner Note:

1. In bracket 7, a full explanation of the deficiency must be provided.
2. If the petition lacks one or more of the required parts set forth in 37 CFR 1.324, it should be dismissed using form paragraph 10.14 or 10.20, rather than being denied.
3. In bracket 11, insert correspondence address of record.
4. This form paragraph is printed with the USPTO letterhead.

¶ 10.18 Waiver of Requirements of 37 CFR 1.324 Under 37 CFR 1.183, Dismissed

Suspension of the rules under 37 CFR 1.183 may be granted for any requirement of the regulations which is not a requirement of the statutes. In this instance, 35 U.S.C. 256 requires [1].

Accordingly, the petition under 37 CFR 1.183 is dismissed as moot.

Examiner Note:

1. This form paragraph should follow form paragraph 10.16 whenever the petition requests waiver of one or more of the provisions of 37 CFR 1.324 that are also requirements of 35 U.S.C. 256.

2. If the petition requests waiver of requirements of 37 CFR 1.324 that are not specific requirements of the statute (i.e., the fee or the oath or declaration by all inventors), the application must be forwarded to a petitions attorney in the Office of the Deputy Commissioner for Patent Examination Policy for decision.

1481.03 Correction of 35 U.S.C. 119 and 35 U.S.C. 120 Benefits [R-7]**I. CORRECTION TO PERFECT CLAIM FOR 35 U.S.C. 119 (a)-(d) AND (f) BENEFITS**

See MPEP § 201.16 for a discussion of when 35 U.S.C. 119 (a)-(d) and (f) benefits can be perfected by certificate of correction.

II. CORRECTION AS TO 35 U.S.C. 120 AND 35 U.S.C. 119(e) BENEFITS**A. For Applications Filed **>Before< November 29, 2000**

For applications filed **>before< November 29, 2000, it is the version of 37 CFR 1.78, which was in effect as of November 29, 2000, that applies. The pre-November 29, 2000 version reads as follows:

37 CFR 1.78. Claiming benefit of earlier filing date and cross-references to other applications.

(a)(1) A nonprovisional application may claim an invention disclosed in one or more prior filed copending nonprovisional applications or copending international applications designating the United States of America. In order for a nonprovisional application to claim the benefit of a prior filed copending nonprovisional application or copending international application designating the United States of America, each prior application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. In addition, each prior application must be:

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Complete as set forth in § 1.51(b); or

(iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16, or

(iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(f) within the time period set forth in § 1.53(f).

(2) Except for a continued prosecution application filed under § 1.53(d), any nonprovisional application claiming the benefit of one or more prior filed compending nonprovisional applications or international applications designating the United States of America must contain a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Unless the reference required by this paragraph is included in an application data sheet (§ 1.76), the specification must contain or be amended to contain such reference in the first sentence following any title. The request for a continued prosecution application under § 1.53(d) is the specific reference required by 35 U.S.C. 120 to the prior application. The identification of an application by application number under this section is the specific reference required by 35 U.S.C. 120 to every application assigned that application number. Cross-references to other related applications may be made when appropriate (see § 1.14(a)).

(3) A nonprovisional application other than for a design patent may claim an invention disclosed in one or more prior filed compending provisional applications. In order for a nonprovisional application to claim the benefit of one or more prior filed compending provisional applications, each prior provisional application must name as an inventor at least one inventor named in the later filed nonprovisional application and disclose the named inventor's invention claimed in at least one claim of the later filed nonprovisional application in the manner provided by the first paragraph of 35 U.S.C. 112. In addition, each prior provisional application must be entitled to a filing date as set forth in § 1.53(c), have any required English-language translation filed therein within the time period set forth in § 1.52(d), and have paid therein the basic filing fee set forth in § 1.16(k) within the time period set forth in § 1.53(g).

(4) Any nonprovisional application claiming the benefit of one or more prior filed compending provisional applications must contain a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of series code and serial number). Unless the reference required by this paragraph is included in an application data sheet (§ 1.76), the specification must contain or be amended to contain such reference in the first sentence following any title.

Under certain conditions specified below, a Certificate of Correction can be used, with respect to 35 U.S.C. 120 and 119(e) priority, to correct:

(A) the failure to make reference to a prior compending application pursuant to 37 CFR 1.78(a)(2) and (a)(4), or

(B) an incorrect reference to a prior compending application pursuant to 37 CFR 1.78(a)(2) and (a)(4).

For all situations other than where priority is based upon 35 U.S.C. 365(c), the conditions are as follows:

(A) for 35 U.S.C. 120 priority, all requirements set forth in 37 CFR 1.78(a)(1) must have been met in the application which became the patent to be corrected;

(B) for 35 U.S.C. 119(c) priority, all requirements set forth in 37 CFR 1.78(a)(3) must have been met in the application which became the patent to be corrected; and

(C) it must be clear from the record of the patent and the parent application(s) that priority is appropriate. See MPEP § 201.11 for requirements under 35 U.S.C. 119(e) and 120.

Where 35 U.S.C. 120 and 365(c) priority based on an international application is to be asserted or corrected in a patent via a Certificate of Correction, the following conditions must be satisfied:

(A) all requirements set forth in 37 CFR 1.78(a)(1) must have been met in the application which became the patent to be corrected.

(B) it must be clear from the record of the patent and the parent application(s) that priority is appropriate (see MPEP § 201.11); and

(C) the patentee must submit with the request for the certificate copies of documentation showing designation of states and any other information needed to make it clear from the record that the 35 U.S.C. 120 priority is appropriate. See MPEP § 201.13(b) as to the requirements for 35 U.S.C. 120 priority based on an international application.

If all the above-stated conditions are satisfied, a Certificate of Correction can be used to amend the patent to make reference to a prior compending application, or to correct an incorrect reference to the prior compending application. Note *In re Schmers*, 218 USPQ 443 (Comm'r Pat. 1983) which suggests that a Certificate of Correction is an appropriate remedy for correcting, in a patent, reference to a prior compending application. Also, note *In re Lambrecht*, 202 USPQ

620 (Comm'r Pat. 1976), citing *In re Van Esdonk*, 187 USPQ 671 (Comm'r Pat. 1975).

If any of the above-stated conditions is not satisfied, the filing of a reissue application (see MPEP § 1401 - § 1460) would be appropriate to pursue the desired correction of the patent.

B. For Applications Filed on or After November 29, 2000

For applications filed on or after November 29, 2000, the version of 37 CFR 1.78 reproduced below applies (note that amendments to 37 CFR 1.78 took effect on November 29, 2000, December 28, 2001, May 1, 2003, January 21, 2004, September 21, 2004, December 8, 2004, * July 1, 2005², and November 25, 2005³).

37 CFR 1.78. Claiming benefit of earlier filing date and cross-references to other applications.

(a)(1) A nonprovisional application or international application designating the United States of America may claim an invention disclosed in one or more prior-filed copending nonprovisional applications or international applications designating the United States of America. In order for an application to claim the benefit of a prior-filed copending nonprovisional application or international application designating the United States of America, each prior-filed application must name as an inventor at least one inventor named in the later-filed application and disclose the named inventor's invention claimed in at least one claim of the later-filed application in the manner provided by the first paragraph of 35 U.S.C. 112. In addition, each prior-filed application must be:

(i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or

(ii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and have paid therein the basic filing fee set forth in § 1.16 within the pendency of the application.

(2)(i) Except for a continued prosecution application filed under § 1.53(d), any nonprovisional application or international application designating the United States of America claiming the benefit of one or more prior-filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain a reference to each such prior-filed application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Cross references to other related applications may be made when appropriate (see § 1.14).

(ii) This reference must be submitted during the pendency of the later-filed application. If the later-filed application is an application filed under 35 U.S.C. 111(a), this reference must also be submitted within the later of four months from the actual

filing date of the later-filed application or sixteen months from the filing date of the prior-filed application. If the later-filed application is a nonprovisional application which entered the national stage from an international application after compliance with 35 U.S.C. 371, this reference must also be submitted within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371 (b) or (i) in the later-filed international application or sixteen months from the filing date of the prior-filed application. These time periods are not extendable. Except as provided in paragraph (a)(3) of this section, the failure to timely submit the reference required by 35 U.S.C. 120 and paragraph (a)(2)(i) of this section is considered a waiver of any benefit under 35 U.S.C. 120, 121, or 365(c) to such prior-filed application. The time periods in this paragraph do not apply if the later-filed application is:

(A) An application for a design patent;

(B) An application filed under 35 U.S.C. 111 (a) before November 29, 2000; or

(C) A nonprovisional application which entered the national stage after compliance with 35 U.S.C. 371 from an international application filed under 35 U.S.C. 363 before November 29, 2000.

(iii) If the later-filed application is a nonprovisional application, the reference required by this paragraph must be included in an application data sheet (§ 1.76), or the specification must contain or be amended to contain such reference in the first sentence(s) following the title.

(iv) The request for a continued prosecution application under § 1.53(d) is the specific reference required by 35 U.S.C. 120 to the prior-filed application. The identification of an application by application number under this section is the identification of every application assigned that application number necessary for a specific reference required by 35 U.S.C. 120 to every such application assigned that application number.

(3) If the reference required by 35 U.S.C. 120 and paragraph (a)(2) of this section is presented after the time period provided by paragraph (a)(2)(ii) of this section, the claim under 35 U.S.C. 120, 121, or 365(c) for the benefit of a prior-filed copending nonprovisional application or international application designating the United States of America may be accepted if the reference identifying the prior-filed application by application number or international application number and international filing date was unintentionally delayed. A petition to accept an unintentionally delayed claim under 35 U.S.C. 120, 121, or 365(c) for the benefit of a prior-filed application must be accompanied by:

(i) The reference required by 35 U.S.C. 120 and paragraph (a)(2) of this section to the prior-filed application, unless previously submitted;

(ii) The surcharge set forth in § 1.17(f), and

(iii) A statement that the entire delay between the date the claim was due under paragraph (a)(2)(ii) of this section and the date the claim was filed was unintentional. The Director may require additional information where there is a question whether the delay was unintentional.

(4) A nonprovisional application, other than for a design patent, or an international application designating the United States of America may claim an invention disclosed in one or

more prior-filed provisional applications. In order for an application to claim the benefit of one or more prior-filed provisional applications, each prior-filed provisional application must name as an inventor at least one inventor named in the later-filed application and disclose the named inventor's invention claimed in at least one claim of the later-filed application in the manner provided by the first paragraph of 35 U.S.C. 112. In addition, each prior-filed provisional application must be entitled to a filing date as set forth in § 1.53(c), and the basic filing fee set forth in § 1.16(d) must be paid within the time period set forth in § 1.53(g).

(5)(i) Any nonprovisional application or international application designating the United States of America claiming the benefit of one or more prior-filed provisional applications must contain or be amended to contain a reference to each such prior-filed provisional application, identifying it by the provisional application number (consisting of series code and serial number).

(ii) This reference must be submitted during the pendency of the later-filed application. If the later-filed application is an application filed under 35 U.S.C. 111(a), this reference must also be submitted within the later of four months from the actual filing date of the later-filed application or sixteen months from the filing date of the prior-filed provisional application. If the later-filed application is a nonprovisional application which entered the national stage from an international application after compliance with 35 U.S.C. 371, this reference must also be submitted within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371(b) or (f) in the later-filed international application or sixteen months from the filing date of the prior-filed provisional application. These time periods are not extendable. Except as provided in paragraph (6) of this section, the failure to timely submit the reference is considered a waiver of any benefit under 35 U.S.C. 119(c) to such prior-filed provisional application. The time periods in this paragraph do not apply if the later-filed application is:

(A) An application filed under 35 U.S.C. 111(a) before November 29, 2000, or

(B) A nonprovisional application which entered the national stage after compliance with 35 U.S.C. 371 from an international application filed under 35 U.S.C. 363 before November 29, 2000.

(iii) If the later-filed application is a nonprovisional application, the reference required by this paragraph must be included in an application data sheet (§ 1.76), or the specification must contain or be amended to contain such reference in the first sentence(s) following the title.

(iv) If the prior-filed provisional application was filed in a language other than English and both an English-language translation of the prior-filed provisional application and a statement that the translation is accurate were not previously filed in the prior-filed provisional application, applicant will be notified and given a period of time within which to file, in the prior-filed provisional application, the translation and the statement. If the notice is mailed in a pending nonprovisional application, a timely reply to such a notice must include the filing in the nonprovisional application of either a confirmation that the translation and statement were filed in the provisional application, or an amendment

or Supplemental Application Data Sheet withdrawing the benefit claim, or the nonprovisional application will be abandoned. The translation and statement may be filed in the provisional application, even if the provisional application has become abandoned.

(6) If the reference required by 35 U.S.C. 119(c) and paragraph (a)(5) of this section is presented in a nonprovisional application after the time period provided by paragraph (a)(5)(ii) of this section, the claim under 35 U.S.C. 119(c) for the benefit of a prior filed provisional application may be accepted during the pendency of the later-filed application if the reference identifying the prior-filed application by provisional application number was unintentionally delayed. A petition to accept an unintentionally delayed claim under 35 U.S.C. 119(e) for the benefit of a prior filed provisional application must be accompanied by:

(i) The reference required by 35 U.S.C. 119(c) and paragraph (a)(5) of this section to the prior-filed provisional application, unless previously submitted;

(ii) The surcharge set forth in § 1.17(t); and

(iii) A statement that the entire delay between the date the claim was due under paragraph (a)(5)(i) of this section and the date the claim was filed was unintentional. The Director may require additional information where there is a question whether the delay was unintentional.

(b) Where two or more applications filed by the same applicant contain conflicting claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention during pendency in more than one application.

(c) If an application or a patent under reexamination and at least one other application naming different inventors are owned by the same person and contain conflicting claims, and there is no statement of record indicating that the claimed inventions were commonly owned or subject to an obligation of assignment to the same person at the time the later invention was made, the Office may require the assignee to state whether the claimed inventions were commonly owned or subject to an obligation of assignment to the same person at the time the later invention was made, and if not, indicate which named inventor is the prior inventor. Even if the claimed inventions were commonly owned, or subject to an obligation of assignment to the same person, at the time the later invention was made, the conflicting claims may be rejected under the doctrine of double patenting in view of such commonly owned or assigned applications or patents under reexamination.

Under no circumstances can a Certificate of Correction be employed to correct an applicant's mistake by adding or correcting a priority claim under 35 U.S.C. 119(e) for an application filed on or after November 29, 2000.

Section 4503 of the American Inventors Protection Act of 1999 (AIPA) amended 35 U.S.C. 119(c)(1) to state that:

No application shall be entitled to the benefit of an earlier filed provisional application under this subsection unless an amendment containing the specific reference to the earlier filed provisional application is submitted at such

time during the pendency of the application as required by the Director. The Director may consider the failure to submit such an amendment within that time period as a waiver of any benefit under this subsection. The Director may establish procedures, including the payment of a surcharge, to accept an unintentionally delayed submission of an amendment under this section *during the pendency of the application.* (emphasis added)

A Certificate of Correction is NOT a valid mechanism for adding or correcting a priority claim under 35 U.S.C. 119(e) after a patent has been granted on an application filed on or after November 29, 2000.

Under certain conditions as specified below, however, a Certificate of Correction can still be used, with respect to 35 U.S.C. 120 priority, to correct:

(A) the failure to make reference to a prior copending application pursuant to 37 CFR 1.78(a)(2), or

(B) an incorrect reference to a prior copending application pursuant to 37 CFR 1.78(a)(2).

Where priority is based upon 35 U.S.C. 120 to a **national application**, the following conditions must be satisfied:

(A) all requirements set forth in 37 CFR 1.78(a)(1) must have been met in the application which became the patent to be corrected;

(B) it must be clear from the record of the patent and the parent application(s) that priority is appropriate (see MPEP § 201.11); and

(C) a grantable petition to accept an unintentionally delayed claim for the benefit of a prior application must be filed, including a surcharge as set forth in 37 CFR 1.17(t), as required by 37 CFR 1.78(a)(3).

Where 35 U.S.C. 120 and 365(c) priority based on an **international application** is to be asserted or corrected in a patent via a Certificate of Correction, the following conditions must be satisfied:

(A) all requirements set forth in 37 CFR 1.78(a)(1) must have been met in the application which became the patent to be corrected;

(B) it must be clear from the record of the patent and the parent application(s) that priority is appropriate (see MPEP § 201.11);

(C) the patentee must submit together with the request for the certificate, copies of documentation showing designation of states and any other informa-

tion needed to make it clear from the record that the 35 U.S.C. 120 priority is appropriate (see MPEP § 201.13(b) as to the requirements for 35 U.S.C. 120 priority based on an international application; and

(D) a grantable petition to accept an unintentionally delayed claim for the benefit of a prior application must be filed, including a surcharge as set forth in 37 CFR 1.17(t), as required by 37 CFR 1.78(a)(3).

If all the above-stated conditions are satisfied, a Certificate of Correction can be used to amend the patent to make reference to a prior copending application, or to correct an incorrect reference to the prior copending application, for benefit claims under 35 U.S.C. 120 and 365(c).

If any of the above-stated conditions is not satisfied, the filing of a reissue application (see MPEP § 1401 - § 1460) may be appropriate to pursue the desired correction of the patent for benefit claims under 35 U.S.C. 120 and 365(c).

1485 Handling of Request for Certificates of Correction [R-7]

A request for a Certificate of Correction should be addressed to:

Commissioner for Patents
Office of Patent Publication
ATTN: Certificate of Correction Branch
P.O. Box 1450
Alexandria, VA 22313-1450

Requests for Certificates of Correction will be forwarded to the Certificate of Correction Branch of the Office of Patent Publication, where they will be listed in a permanent record book.

If the patent is involved in an interference, a Certificate of Correction under 37 CFR 1.324 will not be issued unless a corresponding motion under 37 CFR 41.121(a)(2) or 41.121(a)(3) has been granted by the administrative patent judge. Otherwise, determination as to whether an error has been made, the responsibility for the error, if any, and whether the error is of such a nature as to justify the issuance of a Certificate of Correction will be made by the Certificate of Correction Branch. If a report is necessary in making such determination, the case will be forwarded to the appropriate group with a request that the report be furnished. If no certificate is to issue, the party making